Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties

Abstract: Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension, and atherosclerosis and in inhibiting gastric acid secretion are compounds depicted in formulas (1), (2), and (3): wherein: Y is exo-(lower alkyl) or endo-(lower alkyl); n is 2 or 3; R₁ is CH₂OH, CHO, CO₂R or CO₂H; R₂ is hydrogen or methyl; and R₃ is linear or branched alkyl having 5-10 carbon atoms, optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen, in which a is 0, 1 or 2; b is 3-7; m is 1 or 2; and R is wherein X is in which each R₄ is independently hydrogen or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof.

Description: This invention concerns novel derivatives of certain 8-(lower alkyl)bicyclo[4.2.0]octanes and pharmaceutically acceptable salts and esters thereof, their use in the manufacture of medicaments for treating cardiovascular disorders and for inhibiting gastric acid secretion, pharmaceutical compositions containing these compounds, and methods of preparing such compounds. Bicyclo[4.2.0]oct-2-en-7-one is readily prepared from 1,3-cyclohexadiene (Tetrahedron , 27:615, 1971). This has been used as an intermediate in a prostaglandin synthesis (Tetrahedron Lett ., 3091, 1973). Several prostaglandin analogues are known which contain bicyclic all-carbon skeletons. Carbacyclin contains a bicyclo[3.3.0]octane skeleton, and is described in several publications (J. Chem. Soc., Chem. Commun ., 1067, 1978, Tetrahedron Lett ., 3743, 1978; Tetrahedron Lett ., 433, 1979; Tetrahedron Lett ., 2807, 1979; J. Org. Chem . 44:2880, 1979) and patents (BE-A-874 135; GB-A-2 014 143; FR-A-2 424 908; DE-A-2 904 655; JP-A-79-117 450; NL-A-7 901 076 and 8 003 579; ZA-A-79 00 176). Numerous analogues of carbaprostacyclin are described (US-A-4 306 076; DE-A-3 146 278 and DE-A-3 204 443; Prostaglandins, Leukotrienes, Med., 9:307, 1982; J. Org. Chem. 48 , 5341, 1983; Tetrahedron Lett. 3493, 1983; Biochem. Pharmacol. 32:2405, 1983; Prostaglandins, Leukotrienes, Med. 11:391, 1983). Synthetic prostaglandins (homo PGE₂ and homo PGF 2α ) have been prepared with the hydroxyl function and lower side chain trans-opposed in a 6-membered ring (Tetrahedron Lett ., 3327, 1971). EP-A-196 617 discloses [4.2.0] bicyclooctane derivatives which are useful in treating cardiovascular disorders. One aspect of the present invention relates to compounds of the formulas (1), (2) and (3): wherein: Y is exo-(lower alkyl) or endo-(lower alkyl); n is 2 or 3; R₁ is CH₂OH, CHO, CO₂R or CO₂H; R₂ is hydrogen or methyl; and R₃ is linear or branched alkyl having 5-10 carbon atoms, optionally substituted with (lower alkyl), lower alkoxy, trifluoromethyl, or halogen, in which a is 0, 1 or 2; b is 3-7; m is 1 or 2; and R is wherein X is in which each R₄ is independently hydrogen, or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof. Another aspect of this invention is the use of these compounds in the manufacture of a medicament for treating cardiovascular disorders and inhibiting gastric acid secretion. Yet another aspect of the invention is a pharmaceutical composition containing at least one suitable pharmaceutical excipient and a compound of formula (1), (2), (3), or a pharmaceutically acceptable salt and ester thereof. Lastly, another aspect of the invention is a process for preparing compounds of formulas (1), (2), (3), and their corresponding pharmaceutically acceptable, non-toxic salts and esters, as discussed below. Definitions As used herein, the pharmaceutically acceptable, non-toxic salts of the compounds of formula (1), (2), (3), are carboxylic acid salts obtained by reaction of the COOH moiety in formula (1), (2) or (3) with a suitable organic or inorganic base. Specific preparations are discussed hereinafter. The pharmaceutically acceptable carboxylic esters corresponding to the acids of formula (1), (2), (3), are prepared by conventional methods from the acid, e.g. by reaction with the appropriate diazoalkane, or reaction of an alcohol or phenol with an activated derivative of the acid optionally employing a condensing agent such as dicyclohexyl carbodiimide, by reaction of a salt with an appropriate alkylating agent, or by ester exchange from an existing ester. Specific preparations are described in the procedures and examples below. The term "alkyl" refers to and includes saturated branched and straight chain hydrocarbon radicals containing the number of carbons indicated. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl, neopentyl, isopentyl, hexyl, octyl, nonyl, isodecyl, 6-methyldecyl. "Cycloalkyl" as used herein means a saturated monocyclic hydrocarbon radical containing 3-8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. The term, "lower alkyl" refers to a branched or unbranched saturated hydrocarbon chain of 1-4 carbons, such as, for example, methyl, ethyl, n-propyl, i-butyl and the like. The term "alkoxy" refers to the radical -O-alkyl wherein "alkyl" is as defined above. This includes radicals such as methoxy, ethoxy, 2-propoxy, butoxy, 3-pentoxy and the like. "Lower alkoxy" means the group -O-(lower alkyl), wherein lower alkyl is as defined above. "Halo" as used herein denotes fluoro, chloro, bromo, or iodo. "Phenyl" as used herein encompasses all possible isomeric phenyl radicals optionally monosubstituted with a substituent selected from lower alkyl, lower alkoxy, hydroxy, trifluoromethyl and halogen. "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted phenyl" means that the phenyl may or may not be substituted and that the description includes both unsubstituted phenyl and phenyl wherein there is substitution. The term "treatment" as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease. The numbering system for the bicyclo[4.2.0]octane system shown in the scheme illustrated below is used in naming the intermediates and product compounds of the invention. The absolute stereochemistry at carbons 1,2,3 and 6, and 3′ of the side chain attached to carbon 2 is specified according to the Cahn-Ingold-Prelog R-S system. When the compound is a pure enantiomer, the stereochemistry at each chiral carbon is specified by either R or S. When a compound is a racemic mixture the stereochemistry at each chiral carbon is specified by either R* or S* by reference to a single enantiomer of the racemate. In this manner relative stereochemistry is conveyed unambiguously, and the racemic modification is denoted by the asterisk "*". When the substituent at carbon 8 is cis to the ring junction protons (at carbons 1 and 6) it is specified as an exo-isomer. When the substituent at carbon 8 is trans to the ring junction protons it is specified as an endo-isomer. An alternative method of indicating the stereochemistry in a racemic mixture is to specify each chiral carbon as RS or SR by reference to a single enantiomer. Thus, a compound of our invention named as (Z)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-exo-methylbicyclo [4.2.0]oct-7-ylidene]butyric acid could with equal accuracy be named as (Z)-(3′SR,1SR,2SR,3RS,6SR)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene] butyric acid and a compound of our invention named as (Z)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid may be alternatively named (Z)-(3′SR,1SR,2SR,3RS,6SR)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid. Olefin stereochemistry is specified by the IUPAC E - Z system. Classical nomenclature is used to name a compound having a triple bond as alkynyl; and two bonds emanating from the same atom as -ylidene. The compounds of our invention include compounds wherein R₃ is defined as a cycloalkyl or cycloalkylalkyl group. In the claims and specification of this application this particular definition of R₃ has been generically illustrated as To avoid any ambiguity, it should be clearly understood that this form of illustration is intended to indicate that the groups CH and (CH₂) b are directly linked by two covalent bonds to form a cycloalkyl group having b+1 carbons. The square brackets are not intended to suggest any intervening carbon atoms between the groups CH and (CH₂) b . The formula could equally be written in a manner such that the groups CH and (CH₂) b are joined by curved lines, i.e. For example, in the above formula where a is 0 and b is 5, R₃ is cyclohexyl, and where a is 1 and b is 4, R₃ is cyclopentylmethyl. One preferred subclass of compounds of the invention includes compounds of formula (1), (2) and (3) wherein n is 2. Another preferred subclass are compounds of the invention in which R₂ is hydrogen. Yet another preferred subclass includes compounds in which R₁ is CHO, CO₂R or CO₂H, particularly CO₂R and CO₂H, and most particularly CO₂H. Still another preferred subclass includes compounds of the invention wherein R₃ is linear or branched alkyl having 5-10, preferably 5 or 7, and most preferably 5 carbon atoms, particularly and most particularly Yet another preferred subclass includes compounds of formulas (1), (2) and (3) in which n is 2 or 3, R₁ is CO₂H, CO₂R or CHO, R₂ is hydrogen or methyl, R₃ is linear or branched alkyl of 5 to 10 carbons, or and Y is exo-methyl or endo-methyl. Within this subclass, a preferred group are compounds of formula (1), (2) and (3) in which n is 2 or 3, R₁ is CHO, CO₂R or CO₂H, R₂ is hydrogen or methyl, and R³ is linear or branched alkyl of 5 or 7 carbon atoms, Among these, an especially preferred group are compounds of the invention wherein n is 2 or 3, R₁ is CO₂R or CO₂H, R₂ is hydrogen or methyl, and R₃ is n-pentyl, or A particularly preferred subgroup are compounds of formulas (1), (2) and (3) in which n is 2, R₁ is CO₂H, R₂ is hydrogen, and R₃ is wherein a is 0 or 1 and b is 3-7, preferably 4 or 5, and most preferably 5; and the pharmaceutically acceptable, non-toxic salts and esters thereof. A most particularly preferred subgroup are those represented by formula (1) wherein R₁ is CO₂H; R₂ is H and R₃ is cyclohexyl. The foregoing statement of the preferred embodiments of the invention includes the pharmaceutically acceptable salts and esters, as well as the free bases of the compounds referred to above or named below. At the present time, the most preferred compounds of this invention are: (Z)-(3,S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3,S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-mehylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S,1R,2R,3S,6R)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S,1R,2R,3S,6R)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methyl-bicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S*,1R*,2R*,3S*,6R*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S*,1R*,2R*,3S*,6R*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; and the pharmaceutically acceptable, non-toxic salts and esters thereof. PREPARATION PROCEDURES I. Compounds wherein R₁ is CO₂H. Compounds of formulas (1), (2), or (3) wherein R₁ is CO₂H are prepared according to Reaction Scheme I. In the detailed description, the Roman numerals in parentheses correspond to the compound shown in the reaction scheme. The synthesis of the compounds of formulas (1) , (2), and (3) begins with reaction of 1,3-cyclohexadiene (I) with the appropriate compound of the formula R o CHClCOCl, where R o is lower alkyl, which are readily commercially available. For example, reaction of (I) with 2-chloropropionyl chloride gives a mixture of 8-endo-chloro-8-exo-methylbicyclo[4.2.0]oct-2-en-7-one (IIA) and 8-exo-chloro-8-endo-methylbicyclo[4.2.0]oct-2-en-7-one (IIB), which are isolated and separated conventionally. The 8-exo-chloro-8-endo-loweralkylbicyclo[4.2.0]oct-2-en-7-one (IIB) is then reacted with a dechlorinating agent such as zinc-copper couple or tri-n-butyltin hydride to give an 8-endo-(lower alkyl)bicyclo[4.2.0]oct-2-en-7-one (III). For example, 8-exo-chloro-8-endo-methylbicyclo[4.2.0]oct-2-en-7-one gives 8-endo-methylbicyclo[4.2.0]oct-2-en-7-one. The compound of formula (III), where Y is endo-(lower alkyl), is then reacted with 1,2-bis(trimethylsilyloxy)ethane in the presence of trimethylsilyltrifluoromethanesulfonate as a catalyst. For example, when Y is endo-methyl and the reaction is conducted at a temperature of about -60°C to -80°C, the ketal of formula (IVB) results, namely spiro [8-endo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]. If the reaction is carried out at a temperature of about 10°-30°C, the ketal of formula (IVA) is produced, namely spiro [8-exo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]. The desired ketal is then reacted with N-bromoacetamide and water in acetone to give a mixture of bromohydrins (V), which are converted to a mixture of epoxy acetals (VI) and (VII) upon treatment with potassium carbonate. The bicyclic epoxy acetals (VI) and (VII) can be reacted with an organolithium reagent of general structure Li-R′ (XXI) in the presence of boron trifluoride etherate to give the diastereomeric alcohols, VIII and IX, where in which R₂ and R₃ are as previously defined and Pt is a protecting group for the side chain hydroxyl function. Preparation of the organolithium reagents of formula XXI is described following Reaction Scheme II, below. Suitable protecting groups include, but are not limited to, silyl ethers, tertiary alkyl ethers, e.g. tert-butyl, (optionally substituted) triphenylmethyl ethers, acetals such as tetrahydropyranyl ethers, and the like. Usually trialkyl silyl ethers are preferred, and particularly preferred are the tert-butyldimethylsilyl derivatives. These ethers are prepared from the corresponding carbinols by standard procedures well known to those skilled in the art; the tert-butyldimethylsilyl ethers, in particular, are used extensively in prostaglandin chemistry and can be conveniently prepared by reaction of the appropriate carbinol with tert-butyldimethylsilyl chloride in N,N-dimethylformamide solution in the presence of imidazole, which functions in the dual capacities of specific catalyst for the silylation and as base, to neutralize the hydrochloric acid which constitutes the other reaction product. Organolithium reagents of the alkynyl type are prepared from the corresponding 1-alkyn-3-ols, which in turn can be readily obtained by reaction of an acetylenic Grignard reagent, i.e. ethynyl magnesium halide, or lithium acetylide, with aldehydes or ketones (R₂R₃C=O), furnishing ethynyl carbinols (Preparation of 1-alkyn-3-ols is described in greater detail in Preparation 5.A.) Protection of the hydroxyl moiety with a suitable protecting group, such as are described above, gives the corresponding ethers Conversion to an organolithium reagent can be effected, usually by exchange reaction with a stoichiometric quantity of a more reactive organolithium species, e.g. an alkyl lithium reagent R′Li, to give the acetylenic lithium reagent The reaction of the lithium acetylenic reagent XXI with the mixture of epoxyacetals VI and VII gives a mixture of compounds from which the desired mixture of diastereoisomers VIII and IX is separated by chromatography. For example, reaction of a mixture of VI and VII, where Y is methyl, with (S)-1-lithio-3-(tert-butyldimethyl-silyloxy)-3-cyclohexylprop-1-yne in the presence of boron trifluoride etherate furnishes a mixture from which the diastereoisomeric carbinols as a mixture is separated, i.e., VIII -- (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyloxy)-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; and IX -- (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyloxy)-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]. The mixture of diastereomeric 8-(lower alkyl) bicyclo[4.2.0]octanols VIII and IX is converted into a mixture of the dicobalt hexacarbonyl complexes X and XI by reaction with dicobaltoctacarbonyl in diethyl ether. These complexes are separated chromatographically to give the separate complexes X and XI, which are each reacted with ceric ammonium nitrate to give the compounds of formulas XII and XIII. For example, when Y is methyl, (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)] (XII), and (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0] octane-7,2"-(1",3"-dioxolane)] (XIII), respectively are obtained. These are each reacted with dilute sulfuric acid to effect ketal hydrolysis and also hydrolysis of the silyl protective group to give the compounds of formulas XIV and XV. For example, when Y is methyl, (3'S,1S,2S,3R,6S)-2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one (XIV), and (3'S,1R,2R,3S,6R)-2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0] octan-7-one (XV), respectively are obtained. The bicyclooctanone alkynol of formula XIV is then reacted with an appropriately chosen stabilized anion or ylid of the formula (wherein P' is a residue normally associated with olefination reactions and n is 2 or 3), such as a triphenylphosphorane ylid having a 4 to 5 carbon atom chain length, in an aprotic solvent preferably dimethylsulfoxide or dimethylsulfoxide/tetrahydrofuran mixture at a temperature between 10°C and 60°C for 1-24 hours to yield a mixture of the Z and E alkanoic acids (1) and (2), for example, when Y is endo-methyl, Z-and E-(3'S,1S,2S,3R,6S)-2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene alkanoic acids. This mixture is separated chromatographically to give, for example, Z-(3'S,1S,2S,3R,6S)-2-(3'hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methyl-bicyclo[4.2.0]-oct-7-ylidenealkanoic acid (1) and E-(3'S,1S,2S,3R,6S)-2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidenealkanoic acid (2). Similarly, the bicyclooctanone alkynol of formula XV is reacted with an appropriately chosen stabilized anion or ylid of the formula such as triphenylphosphorane ylid having a 4 to 5 carbon atom chain length to give a mixture of Z and E alkanoic acids (3) and XVI. This mixture is separated chromatographically to give, for example, Z-(3'S,1R,2R,3S,6R)-2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene alkanoic acid (3) and E-(3'S,1R,2R,3S,6R)-2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene alkanoic acid XVI. For the preparation of the triphenylphosphorane ylids used for the Wittig reactions that convert XIV and XV to (1), (2), and (3), the corresponding triphenylphosphonium salts are deprotonated with two equivalents of dimsyl sodium in dimethyl sulfoxide. The triphenylphosphonium salts are prepared by condensing triphenylphosphine with an ω-halocarboxylic acid as described in J. Org. Chem. 27, 3404 (1962). The crude phosphonium salts are purified typically by washing with diethyl ether or by recrystalization from acetonitrile or ethanol-diethyl ether. The structures depicted herein, including the novel compounds of our invention, have multiple chiral centers and are optically active. While, for illustrative purposes, only one optical isomer is depicted, our invention encompasses all optical isomers and mixtures thereof, said mixtures including racemates, diastereomeric mixtures and epimeric mixtures of endo/exo-(lower alkyl) isomers in all proportions. If the product compounds of our invention are prepared from optically inactive starting materials and without employment of chiral reagents, the products will be obtained as (optically inactive) racemic mixtures. The optically active acetylenes used in Scheme I in which R₂ is hydrogen are prepared according to Scheme II. As shown in Scheme II a propargylic alcohol of formula XVII, wherein R₂ is H, is oxidized with Jones reagent to give a propargylic ketone of formula XVIII. This ketone is reduced with isopinocamphenyl-9-borabicyclo[3.3.1]nonane according to the method described in J.Amer.Chem.Soc., 101, 2352 (1979) to give the chiral propargylic alcohols (XIX). The propargylic alcohols XIX are converted into O-protected derivatives XX by condensation with trialkylsilyl chlorides and imidazole. Compounds XX are reacted with butyllithium to give lithioacetylides XXI, which are used in Scheme I to convert epoxide VI into VIII and IX. Propargylic alcohols of formula XVII wherein R₂ is methyl are prepared according to the general method of Organic Synthesis , Collective Volume 3, page 320 (1955). The optically active acetylenes used in Scheme I wherein R₂ is H or CH₃ may also be prepared according to Scheme III. Scheme III is the method of Fried ( Ann.N.Y.Acad.Sci ., 180, 39 (1971)). In this method a hemiphthalate of racemic XVII, which is formed by condensation of XVII with phthalic anhydride, is converted into a mixture of diastereoisomeric salts XXII and XXIII using a suitable optically active amine. The mixture of salts is recrystallized from an appropriate solvent, typically acetonitrile, to give a pure diastereoisomeric salt XXII. This salt is treated with aqueous sodium carbonate then acidified with dilute aqueous hydrochloric acid to give hemiphthalate XXIV, which is hydrolyzed with aqueous base to give chiral acetylenic alcohol XXV. The preceding discussion of Schemes I, II and III in part describes a method of synthesizing and separating the chiral intermediates of formula XII and XIII obtained from the reaction of the mixture of epoxides VI and VII with a chiral lithium acetylide of formula XXI. An alternative method of preparing these chiral intermediate of Scheme I starting with a racemic compound of formula XXI is illustrated in Scheme IV. The starting point of Scheme IV is a racemic mixture indicated as d,l XII, which is a mixture of the isomers shown as formulas XII and XIIA. The mixture d,l XII is obtained by reacting the mixture of epoxides VI and VII with a racemic lithium acetylide of formula XXI. The reaction also gives the corresponding racemic mixture d,l XIII, consisting of the compound of formula XIII and its enantiomer. The two diastereoisomers d,l XII and d,l XIII are separated by the cobalt procedure, as shown in Scheme I above. Condensation of d,l XII with (R)-(-)-α-(1-naphthyl)ethylisocyanate gives a mixture of diastereoisomers (XXVI) and (XXVII). These are separated by chromatography to give the individual diastereoisomers (XXVI) and (XXVII). Compounds (XXVI) and (XXVII) are reacted individually with lithium aluminum hydride to give enantiomers (XIIA) and (XII) respectively. Similarly, following the above procedure the compound of formula XIII is separated from its enantiomer. The pharmaceutically acceptable non-toxic salt derivatives of the compounds of formulas (1), (2), (3) are prepared by treating the free acids with an appropriate amount of pharmaceutically acceptable base. Representative pharmaceutically acceptable bases are sodium hydroxide, potassium hydroxide, lithium hydroxide, ammonium hydroxide, calcium hydroxide, magnesium hydroxide, ferrous hydroxide, zinc hydroxide, copper hydroxide, manganous hydroxide, aluminum hydroxide, ferric hydroxide, manganic hydroxide, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. For preparing, for example, monovalent cation salts, the free acid starting material of formula (1), (2), or (3) is treated with one molar equivalent of pharmaceutically acceptable base in an appropriate solvent such as water, methanol, ethanol, isopropanol, butanol, acetone, dioxane or tetrahydrofuran. The molar ratio of compounds of formula (1), (2), or (3) to base used are chosen to provide the ratio desired for any particular salt. For preparing, for example, divalent cation salts such as the calcium or magnesium salts the free acid starting material of formula (1), (2) or (3) is treated with at least one-half molar equivalent of pharmaceutically acceptable base to yield a neutral salt. Similarly, for the trivalent cation aluminum salts, at least one-third molar equivalent of the aluminum base is employed if a neutral salt product is desired. The novel free carboxylic acids (1), (2) and (3) of our invention can be reliberated from their respective salts by treating said salts with at least stoichiometric quantities of a strong acid, preferably an inorganic acid, e.g., hydrochloric acid, sulfuric acid, and the like, at temperatures ranging from about 0°C to about 50°C, preferably at room temperature. The pharmaceutically acceptable non-toxic esters of the novel acids (1), (2), and (3) of our invention can be prepared, e.g. by esterifying the corresponding free acids with a solution of the appropriate diazoalkane in a suitable inert solvent such as diethyl ether. An alternative and general method for producing the esterified acids of our invention comprises reaction of a benzene solution of the carboxylic acid with an alkyl halide in the presence of the organic base diazabicycloundecane (DBU) at temperatures from about 20°C-80°C, and for about 1-12 hours. These conditions are particularly useful for esterifying acids containing labile functionality in the molecule, such as the prostaglandins and their synthetic analogues, since they avoid the use of acid catalysts and in fact involve no harsh reagents. (N. Ono et al, Bull.Chem.Soc.Japan , 51, 2401-2404 (1978)). The esters can also be prepared under mild conditions by reacting the novel acids (1), (2) or (3) with an alcohol or phenol in the presence of a dehydrating agent, for example, dicyclohexylcarbodiimide. The reaction involves reacting equivalent amounts of the acid and alcohol or phenol in a suitable solvent, for example, methylene chloride and dimethylformamide mixture, in the presence of a catalytic amount of 4-dimethylaminopyridine and an equimolar amount of dicyclohexylcarbodiimide. The reaction is carried out at a temperature of about -10°C to 25°C, preferably about 0°C, for 8 to 48 hours, preferably about 16 hours. Typical esters are those esters derived from methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol, 2-butyl alcohol, 2-pentyl alcohol, isopentyl alcohol, 2-hexyl alcohol, and the like. Alternatively, the alkyl esters can be prepared by transesterification, catalyzed by the corresponding alkoxide according to methods known in the art. It is preferred in preparing the esters via transesterification to go from a lower ester to a higher ester, e.g., from the methyl ester to the isoamyl ester. However, by using a substantial excess of a lower alcohol, a higher ester can be transesterified to a lower ester; thus, for example, by using a substantial excess of ethanol, the hexyl ester is converted by transesterification to the ethyl ester. Salts of the compounds of formula (1), (2), and (3) may be interchanged by taking advantage of differential solubilities of the salts volatilities or activities of the acids, or by treating with the appropriately loaded ion exchange resin. For example, the interchange is effected by the reaction of a salt of the compounds of formula (1), (2), and (3) with a slight stoichiometric excess of an acid of a lower pKa than the acid component of the starting salt. This conversion is carried out at a temperature between about 0°C and the boiling point of the solvent being used as the medium for the procedure. II. Compounds Wherein R₁ is CH₂OH or CHO . Compounds of formulas (1), (2), or (3) wherein R₁ is CH₂OH or CHO are prepared from the corresponding compounds (1), (2), or (3) wherein R₁ is CO₂H, according to Scheme V. Scheme V demonstrates a method for the conversion of (1) wherein R₁ is CO₂H into (1) wherein R₁ is CH₂OH or CHO. By appropriate substitution of (1) wherein R₁ is CO₂H the reactions of Scheme V may be used to prepare (2) or (3) wherein R₁ is CH₂OH or CHO. For example, reaction of (1) wherein R₁ is CO₂H with diazomethane gives the methyl ester XXVIII. Reaction of XXVIII with excess tert-butyldimethylchlorosilane in the presence of triethylamine and 4-dimethylaminopyridine gives the bis-protected derivative XXIX (Pt = Si(CH₃)₂t-Bu). Reduction of XXIX with lithium aluminum hydride gives carbinol XXX, which is converted to (1) wherein R₁ is CH₂OH by reaction with tetrabutylammonium fluoride in tetrahydrofuran. Oxidation of XXX with, for example, pyridinium chlorochromate gives aldehyde XXXI, which is converted into (1) wherein R₁ is CHO by reaction with tetrabutylammonium fluoride in tetrahydrofuran. The compounds wherein R₁ is CH₂OH may also be prepared as E/Z mixtures by reacting compounds XIV or XV with a stabilized anion or ylid of the formula (wherein P′ is a residue normally associated with olefination reactions and n is 2 or 3), for example, 4-hydroxybutyltriphenylphosphonium bromide in an aprotic solvent, preferably dimethylsulfoxide or dimethylsulfoxide/tetrahydrofuran mixture at a temperature range from 10°C to 60°C for 1-24 hours. Alternatively, the compounds in which R₁ is CH₂OH may also be prepared by first reacting compounds XIV or XV with a compound of the formula (in which Pt is a protecting group for the hydroxyl function), for example, the ylide derived from 4-(t-butyldimethylsilyloxy)butyltriphenylphosphonium bromide, to form the E/Z mixtures of (1) & (2) or (3) and its corresponding E isomer, wherein R₁ is CH₂OPt. The protecting group may be removed according to the procedure described in J. Amer. Chem. Soc., 94 , 6190 (1972) by treatment with dilute aqueous acid such as mineral acid or preferably sulfuric acid in acetonitrile, or with hydrogen fluoride or tetrabutylammonium fluoride in tetrahydrofuran at a temperature in the range of 0°C to 40°C for 1-24 hours. The E/Z isomers prepared by the above two methods may then be separated by chromatography to give the individual E and Z isomers. III. Compounds Wherein R₁ is CO₂R Compounds (1), (2), or (3) wherein R₁ is CO₂R are prepared according to Scheme VI. Scheme VI demonstrates a method for conversion of (1) wherein R₁ is CO₂H into (1) wherein R₁ is CO₂R. By appropriate substitution of (1) wherein R₁ is CO₂H by either (2) or (3) wherein R₁ is CO₂H the reactions of Scheme VI may be used to prepare (2) or (3) wherein R₁ is CO₂R. In this method a compound of formula (1), (2) or (3) wherein R₁ is CO₂H is condensed with isobutyl chlorocarbonate to give an anhydride represented in the case of (1) by formula XXXII, Compound XXXII is reacted with a substituted phenol to give compounds (1) wherein R₁ is CO₂R. The phenols used in this Scheme are known in the prior art and their application to the preparation of phenyl esters is described in J . Pharm . Sci . 68,833 (1979). The compounds of the present invention wherein R₁ is CO₂H and n is 2 may also be prepared according to Scheme VII. Compounds XIV & XV are converted into the corresponding 3 and 3′ protected compounds (XXXIII and XXXIV respectively) by condensation with, for example, trialkylsilyl chloride and imidazole. Compounds XXXIII and XXXIV are then reacted with a vinyl Grignard or vinyl lithium to give vinyl carbinols (XXXV & XXXVI). Claisen rearrangement of the vinyl carbinols is carried out with ethyl orthoacetate in the presence of acid catalyst according to the methods described in J. Amer. Chem. Soc., 92 , 741 (1970) to give compounds XXXVII & XXXVIII as E/Z mixtures. Separation of the E and Z isomers may be accomplished by chromatography. Saponification of the separated esters with lithium hydroxide in aqueous methanol gives the corresponding acids. Subsequently, the protecting groups at the 3- and 3′-positions may be removed by treatment with dilute aqueous acid preferably mineral acid such as sulfuric acid in acetonitrile or with hydrogen fluoride or tetrabutylammonium fluoride in tetrahydrofuran at 0-40°C as described in J. Amer. Chem. Soc., 94 , 6190 (1972) to form the corresponding compounds of formula (1), (2), (3) or (XVI). UTILITY AND ADMINISTRATION The compounds of the present invention are useful for the treatment of cardiovascular disorders; in particular they are vasodilaters, and inhibit accumulation of cholesterol in the vascular wall and in plasma. They are also potent inhibitors of the aggregation of platelets and the release from them of pro-coagulant and pro-atherosclerotic factors. Accordingly, these compounds are useful in treating and preventing cardiovascular disorders involving atherosclerosis, thrombotic and vasospastic conditions. They also are useful antihypertensive and cholesterol lowering agents. The compounds of this invention display the spectrum of activities associated with prostacyclin. However, in contrast to prostacyclin, whose therapeutic potential is severely compromised by its extreme chemical instability, the compounds of our invention retain high biological activity while displaying much greater chemical stability, a combination of attributes identifying them as promising agents for prophylactic and/or therapeutic use particularly in the treatment of cardiovascular dysfunction and disease. Many of these compounds are selective in their antithrombotic effect, and they achieve this therapeutic effect without substantially affecting blood pressure. The compounds of the present invention are also useful in inhibiting gastric acid secretion. Administration of the active compounds in the pharmaceutical composition described hereinafter can be via any of the accepted modes of administration for agents which affect the cardiovascular system. These methods include oral, parenteral, topical and otherwise systemic administration. Depending on the intended mode, the composition may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspension, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The composition will include a conventional pharmaceutical carrier or excipient and an active compound of formula (1), (2), or (3) and/or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc. The present invention further relates to a method for preparing a medicament for treating cardiovascular disorders and inhibiting gastric acid secretion in mammals, which method comprises the use of a compound selected from those represented by formulas (1), (2), (3) or their pharmaceutically acceptable non-toxic salts or esters for preparing said medicament. The present invention still further relates to pharmaceutical compositions useful for treating cardiovascular disorders. These compositions comprise an effective amount of a compound selected from those represented by formulas (1), (2) and (3) or their pharmaceutically acceptable non-toxic salts or esters in acceptable, non-toxic carrier. The amount of active compound administered will of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dosage will be in the range of 0.001-15 mg/kg/day, preferably 0.01-3 mg/kg/day. For an average 70 kg human, this would amount to 0.07-1000 mg per day, or preferably 0.7-210 mg/day. The novel compounds of this invention may be formulated with suitable pharmaceutical vehicles known in the art to form particularly effective cardiovascular compositions. Generally, an effective amount of active ingredient is about 0.001% w to about 10% w of the total formulated composition. The rest of the formulated composition will be about 90% w to about 99.999% w of a suitable excipient. For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier. Liquid pharmaceutically administerable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated. Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., US-A-3 710 795. For systemic administration via suppository, traditional binders and carriers include, e.g. polyalkylene glycols or triglycerides. Such suppositories may be formed from mixtures containing active ingredient in the range of 0.5%-10%; preferably 1-2%. The following Preparations and Examples serve to illustrate the invention and make the invention enabling. They should not be construed as narrowing it or limiting its scope in any way. Preparation 1 A. Preparation of 8-endo-chloro-8-exo-methylbicyclo[4.2.0]oct-2-en-7-one and 8-exo-chloro-8-endo-methyl[4.2.0]oct-2-en-7-one and Related Compounds of Formula IIA and IIB. A mixture of 34.0 g. of cyclohexadiene and 39.7 g of 2-chloropropionyl chloride in 300 ml of diethyl ether under nitrogen was refluxed while adding 31.5 g. of triethylamine in 300 ml of diethyl ether dropwise over a period of 3 hours. The mixture was then stirred at room temperature for 20 hours and filtered. The filtrate was washed with brine, 1N hydrochloric acid, saturated sodium bicarbonate and then dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and the residue distilled to give 32 g of a mixture of the 8-exo-methyl and 8- endo-methyl isomers. The isomers were separated by chromatography on silica gel, eluting with hexane-methylene chloride (1:1) giving 22 g of 8-exo-chloro-8-endo-methylbicyclo[4.2.0]oct-2-en-7-one and 6.4 g of 8-endo-chloro-8-exo-methylbicyclo[4.2.0]-oct-2-en-7-one. B. Similarly, starting with the appropriate 2-chloroalkanoyl chloride in place of 2-chloropropionyl chloride, the following representative compounds of formula (IIA) and (IIB) are prepared: 8-exo-chloro-8-endo-ethylbicyclo[4.2.0]octo-2-en-7-one; 8-endo-chloro-8-exo-ethylbicyclo[4.2.0]oct-2-en-7-one; 8-exo-chloro-8-endo-n-propylbicyclo[4.2.0]octo-2-en-7-one; 8-endo-chloro-8-exo-n-propylbicyclo[4.2.0]oct-2-en-7-one; 8-exo-chloro-8-endo-n-butylbicyclo[4.2.0]octo-2-en-7-one; and 8-endo-chloro-8-exo-n-butylbicyclo[4.2.0]oct-2-en-7-one. Preparation 2 A. Preparation of 8-endo-methylbicyclo[4.2.0]oct-2-en-7-one and Related Compounds of Formula IIIB. To a mixture of 40 g of 8-exo-chloro-8-endo-methylbicyclo[4.2.0]oct-2-en-7-one, prepared as shown in Preparation 1, and 60 g of ammonium chloride in 250 ml of ethanol at room temperature was added 40 g of zinc-copper couple in portions. The reaction mixture was stirred at room temperature for 3 hours, then diluted with diethyl ether and filtered. The filtrate was washed with brine, dried over sodium sulfate and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel, eluting with hexane-methylene chloride (1:1) to give 25.9 g of 8-endo-methylbicyclo[4.2.0]oct-2-en-7-one. B. Similarly, starting with the appropriate compound of formula (IIB) in place of 8-exo-chloro-8-endo-methylbicyclo[4.2.0]oct-2-en-7-one, the following compounds of formula (IIIB) are prepared: 8-endo-ethylbicyclo[4.2.0]oct-2-en-7-one; 8-endo-n-propylbicyclo[4.2.0]oct-2-en-7-one; and 8-endo-n-butylbicyclo[4.2.0]oct-2-en-7-one. Preparation 3 A. Preparation of spiro[8-endo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)] and Related Compounds of Formula IV. A mixture of 680 mg of 8-endo-methylbicyclo[4.2.0]oct-2-en-7-one, prepared as described in Preparation 2, and 2.1 g of 1,2-bis(trimethylsilyloxy)ethane was cooled to -78°C under nitrogen, and 40 µl of trimethylsilyltrifluoromethanesulfonate was added in 4x10 µl portions. The mixture was stirred for a total of 16 hours at -78°C, then quenched by addition of excess pyridine. The reaction mixture was poured into an aqueous saturated sodium bicarbonate solution and extracted with ether. Solvent was removed from the extract under reduced pressure and the residue chromatographed on silica gel, eluting with 5% acetone in hexane, to give 800 mg of spiro[8-endo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]. B. Preparation of spiro[8-exo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)] Following the procedure of paragraph 3.A. above, starting with 8-endo-methylbicyclo[4.2.0]oct-2-en-7-one and carrying out the reaction at room temperature instead of -78°C, spiro[8-exo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)] was similarly prepared. C. Similarly, starting with the appropriate compound of formula (III) in place of 8-endo-methylbicyclo[4.2.0]oct-2-en-7-one, the following compounds of formula (IV) are prepared: spiro[8-endo-ethylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]; spiro[8-exo-ethylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]; spiro[8-endo-n-propylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]; and spiro[8-exo-n-propylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]; spiro[8-endo-n-butylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]; and spiro[8-exo-n-butylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)]; Preparation 4 A. Preparation of (1S*,2S*,4R*,7S*)-Spiro[3-oxa-9-endo-methyltricyclo-[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)], (1S*, 2R*, 4S*, 7S*)-Spiro[3-oxa-9-endo-methyltricyclo[5.2.0.0 2,4 ]-nonane-8,2′-(1′,3′-dioxolane)], and Related Compounds of formulas VI and VII. To a stirred solution of 5 g of spiro[8-endo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)], prepared according to Preparation 3, in 40 ml acetone and 20 ml water at 0°C was added 4.76 g of N-bromacetamide over 1 hour. This mixture was stirred at room temperature for 20 hours. To this solution was added 12.4 g potassium carbonate and the resulting mixture was stirred at room temperature for 2 days. The mixture was saturated with sodium chloride and the resulting mixture extracted with four 150 ml portions of diethyl ether. The combined organic extract was washed with 100 ml of saturated sodium chloride solution and dried over sodium sulfate. Removal of solvent in vacuum and chromatographic purification of the residue on silica gel eluting with 25% acetone-hexane gave 3.45 g of a ca. 9:1 mixture of (1S*,2S*,4R*,7S*)-spiro[3-oxa-9-endo-methyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)] (VI) and (1S*,2R*,4S*,7S*)-spiro[3-oxa-9-endo-methyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)] (VII). B. Similarly, starting from spiro[8-exo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)] and following the procedure of paragraph 4.A., a mixture of (1S*,2S*,4R*,7S*)-spiro[3-oxa-9-exo-methyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)] (VI) and (1S*,2R*,4S*,7S*)-spiro[3-oxa-9-exo-methyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)] (VII) was obtained. C. Similarly, starting with the appropriate compound of formula (IV) in place of spiro[8-endo-methylbicyclo[4.2.0]oct-2-ene-7,2′-(1′,3′-dioxolane)], the following compounds of formula (VI) and (VII) where Y is exo or endo-(lower alkyl) are prepared. (1S*,2S*,4R*,7S*)-spiro[3-oxa-9-ethyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)]; and (1S*,2R*,4S*,7S*)-spiro[3-oxa-9-ethyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)]; (1S*,2S*,4R*,7S*)-spiro[3-oxa-9-n propyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)]; and (1S*,2R*,4S*,7S*)-spiro[3-oxa-9-n-propyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)]; (1S*,2S*,4R*,7S*)-spiro[3-oxa-9-n-butyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)]; and (1S*,2R*,4S*,7S*)-spiro[3-oxa-9-n-butyltricyclo[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)] Preparation 5 Preparation of 3-Hydroxy-1-Alkynes of Formula XVII A. A rapid stream of acetylene was passed through a solution of 2M methyl magnesium bromide (100 ml) in THF until no more methane evolution was observed. 10 g of hexanal was added at 0°C, stirred for 1/2 h and a saturated solution of NH₄Cl was added. The organic product was isolated by extraction with ether. The ether solution was washed with water, brine, dried over MgSO₄ and evaporated to give a liquid, which was purified by distillation, to give 3-hydroxyoct-1-yne. B. Similarly, the following representative compounds of Formula XVII are prepared: 3-Cyclohexylprop-1-yn-3-ol; 1-decyn-3-ol; 1-tridecyn-3-ol; (R)-5-methyl-1-nonyl-3-ol; 1-nonyl-3-ol; 4-phenyl-1-butyn-3-ol; 5-phenyl-1-pentyn-3-ol; 3-methyl-4-phenyl-1-butyn-3-ol; 4-m-trifluoromethylphenyl-1-butyn-3-ol; 4-endo-bicyclo[3.1.0]hex-6-yl-l-butyn-3-ol; 4-exo-bicyclo[3.1.0]hex-6-yl-l-butyn-3-ol; 3-methyl-3-cyclobutyl-1-propyn-3-ol; 3-methyl-3-cyclopentyl-1-propyn-3-ol; 3-cyclopentyl-1-propyn-3-ol; 4-cyclopentyl-1-butyn-3-ol, and 4-cyclohexyl-1-butyn-3-ol. Preparation 6 Preparation of 3-Cyclohexyl-1-propyn-3-one and Related Compounds of Formula XVIII. A. A solution of chromic acid was prepared by dissolving 106.88 g chromium trioxide in 400 ml water and then adding 92 ml concentrated sulfuric acid. This solution was added in dropwise fashion over a 3 hour period to an ice cooled, stirred solution of 120 g 3-cyclohexyl-1-propyn-3-ol in 175 ml acetone. The resulting mixture was diluted with 500 ml water and the product was extracted into 1 liter of diethyl ether. The ether extract was washed with 250 ml saturated sodium bisulfite solution and was dried over sodium sulfate. The diethyl ether was removed by distillation under nitrogen atmosphere and the resulting residue was purified by Kugelrohr distillation (65°C, 0.1 mm Hg = 13.3 Pa) to give 84.9 g of 3-cyclohexyl-1-propyn-3-one as an oil: MS m/z = 136 (M+) Calcd. for C₉H₁₂O: C, 79.37; H, 8.88. Found: C, 79.24; H, 8.6 B. In like manner, but replacing the 3-cyclohexyl-1-propyn-3-ol with 1-octyn-3-ol, 1-octyn-3-one was prepared. C. Similarly, but starting with other appropriate compounds of Formula XVII, prepared in accordance with Preparation 3.B., the following compounds of Formula XVIII are prepared: 1-decyn-3-one; 1-tridecyn-3-one; (R)-5-methyl-1-nonyn-3-one; 1-nonyn-3-one; 4-phenyl-1-butyn-3-one; 5-phenyl-1-pentyn-3-one; 4-m-trifluoromethylphenyl-1-butyn-3-one; 4-endo-bicyclo[3.1.0]hex-6-yl-1-butyn-3-one; 4-exo-bicyclo[3.1.0]hex-6-yl-1-butyn-3-one; 3-cyclopentyl-1-propyn-3-one; 4-cyclopentyl-1-butyn-3-one; and 4-cyclohexyl-1-butyn-3-one. Preparation 7 Preparation of (S)-3-cyclohexyl-1-propyn-3-ol and Related Compounds of Formula XIX. A. A mixture of 1.6 liters 0.5 M 9-borabicyclo[3.3.1]-nonane in tetrahydrofuran and 122.6 g (-)-α-pinene, 99+% pure, was heated at reflux under nitrogen for 4 hr., at which time the excess (-)-α-pinene and tetrahydrofuran were removed under vacuum to leave a thick oil. The contents of the flask were cooled to 0°C and 80 g of 3-cyclohexyl-1-propyn-3-one, prepared according to Preparation 6, was added with stirring. The resulting mixture was allowed to warm to 23°C and it was stirred at that temperature for 16 hr. Excess S-Alpine borane was destroyed by adding 44 ml propionaldehyde and stirring at 23°C for 1 hr. The liberated (-)-α-pinene was removed by vacuum distillation. The resulting mixture was diluted with 400 ml tetrahydrofuran followed by 300 ml 3N sodium hydroxide. To this stirred mixture was added in dropwise fashion 300 ml 30% hydrogen peroxide over 1 hr. The mixture was heated at 40°C for 3 hr. After cooling, the mixture was extracted with diethyl ether and this extract was dried over magnesium sulfate. Evaporation of the solvent and purification of the residue by silica gel flash chromatography using 5% ethyl acetate-hexane gave 56 g of (S)-3-cyclohexyl-1-propyn-3-ol, which by nmr analysis was shown to have 90%, e.e. Recrystallization from hexane gave 45 g of the pure S isomer, mp 56-58°C,[α] 25 / D = -9.24° (C = 0.53, Et₂O). B. In like manner, but replacing the 3-cyclohexyl-1-propyn-3-one with l-octyn-3-one, prepared as described in Preparation 6.B., we prepared (S)-1-octyn-3-ol; [α] 25 / D =-39.7° (C=1, CHCl₃). C. Similarly, but utilizing instead other suitable compounds of Formula XVIII prepared according to Preparation 6.C., the following compounds of Formula XIX are prepared: (S)-1-decyn-3-ol; (S)-1-tridecyn-3-ol; (3S,5R)-5-methyl-1-nonyn-3-ol; (S)-1-nonyn-3-ol; (S)-4-phenyl-1-butyn-3-ol; (S)-5-phenyl-1-pentyn-3-ol; (S)-4-m-trifluoromethylphenyl-1-butyn-3-ol; (S)-4-endo-bicyclo[3.1.0]hex-6-yl-1-butyn-3-ol; (S)-4-exo-bicyclo[3.1.0]hex-6-yl-1-butyn-3-ol; (S)-3-cyclopentyl-1-propyn-3-ol; (S)-3-cyclooctyl-1-propyn-3-ol; (S)-4-cyclopentyl-1-butyn-3-ol; and (S)-4-cyclohexyl-1-butyn-3-ol. Preparation 8 Preparation of (S)-3-cyclohexyl-1-propyn-3-ol and Related Compounds of Formula XIX and XXV. A. A mixture of 50 g racemic 3-cyclohexyl-1-propyn-3-ol, prepared according to Preparation 5, 53.3 g phthalic anhydride, and 100 ml pyridine is heated at 90°C for 4 hours. After cooling to 0°C this mixture is added with stirring to a mixture of 350 ml concentrated hydrochloric acid and 900 ml ice. The oily solid that separates is dissolved in 600 ml diethyl ether. This solution is washed with saturated NaCl solution and is dried over sodium sulfate. Evaporation and recrystallization from acetone/hexane gives the hemi-phthalate, mp 136-138°C. This hemi-phthalate (38.5 g) is suspended in 80 ml dichloromethane and a solution of 16.2 g (-)-α-phenylethylamine in 250 ml dichloromethane is added with stirring over 15 minutes. The mixture is filtered after 1 hour and the filtrate is evaporated to give a mixture of diastereoisomeric salts. This mixture is recrystallized five times from acetonitrile to give 7 g of a pure diastereoisomeric salt mp 142-143°C, [α] D =-36.7 (C=1, CHCl₃). This salt (2 g) is added to a stirred mixture of 25 ml 5% sodium bicarbonate and 24 ml diethyl ether. The ether layer is discarded and the aqueous layer is extracted with 3 additional 25-ml portions of diethyl ether. The aqueous layer is acidified with 4 N HCl and is extracted thoroughly with diethyl ether. The ether extract is dried over sodium sulfate and is evaporated to dryness to give 1.37 g of the hemiphthalate of (S)-3-cyclohexylprop-1-yn-3-ol, mp 70-74°C, [α] D = -35.8° (C=1, CHCl₃). The hemiphthalate was then stirred with excess aqueous 2N potassium hydroxide for 2 hours at 60°C, the mixture cooled to room temperature and extracted with diethyl ether. The organic layer was separated, dried over sodium sulfate and the solvent removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 10% ethyl acetate in hexane, to give (S)-3-cyclohexylprop-1-yn-3-ol, m.p.56°-58°C (C=0.6, Et₂0). B. Similarly, but starting with other compounds of Formula XVII, prepared in accordance with Preparation 3.B., the following compounds of formula XIX and XXV are prepared: (S)-1-octyn-3-ol; (S)-1-decyn-3-ol; (S)-1-tridecyn-3-ol; (3S,5R)-5-methyl-1-nonyn-3-ol; (S)-1-nonyn-3-ol; (S)-4-phenyl-1-butyn-3-ol; (S)-5-phenyl-1-pentyn-3-ol; (S)-4-m-trifluoromethylphenyl-1-butyn-3-ol; (S)-4-endo-bicyclo[3.1.0]hex-6-yl-1-butyn-3-ol; (S)-4-exo-bicyclo[3.1.0]hex-6-yl-1-butyn-3-ol; (S)-3-cyclopentyl-3-methyl-1-propyn-3-ol; (S)-3-cyclobutyl-3-methyl-1-propyn-3-ol; (S)-3-cyclooctyl-1-propyn-3-ol; (S)-4-cyclopentyl-1-butyn-3-ol; (S)-3-cyclopentyl-1-propyn-3-ol; and (S)-4-cyclohexyl-1-butyn-3-ol. Preparation 9 Preparation of (S)-3-Tert-butyldimethylsilyoxyoct-1-yne and Related Silyl Ethers of Formula XX. A. To a solution of (S)-3-cyclohexyl-1-propyn-3-ol, (obtained according to Preparation 7.A. and 8.A.) (2.76 g, 0.02 mol), in 10 ml N,N-dimethylformamide (DMF), cooled to 0°C, was added imidazole (2.1 g), followed by tertbutyldimethylchlorosilane (3.1 g, 0.02 mol). The mixture was stirred for 3 h. Water (80 ml) and hexane (80 ml) were added; the organic layer was separated and combined with 2 x 80 ml of hexane extractions of the aqueous layer. The solvent was removed (in vacuo), after drying over sodium sulfate, to give a crude residue (4.3 g) which was chromatographed on silica gel (80 g), eluting with ethyl acetate-hexane (2:1, v/v) to afford 3-tert-butyldimethylsilyloxy-3-cyclohexylprop-1-yne. B. In like manner, but replacing the 3-cyclohexyl-1-propyn-3-ol with (S)-1-octyn-3-ol, prepared according to Preparation 7.B. and 8.B., there was prepared (S)-3-t-butyldimethylsilyloxyoct-1-yne. C. Similarly, but starting instead with other suitable compounds of formula XIX, prepared according to Preparation 7.C. or 8.B., the following compounds of formula XX are prepared: (S)-3-t-butyldimethylsilyloxy-1-decyne; (S)-3-t-butyldimethylsilyloxy-1-tridecyne; (3S,5R)-3-t-butyldimethylsilyloxy-5-methyl-1-nonyne; (S)-3-t-butyldimethylsilyloxy-1-nonyne; (S)-3-t-butyldimethylsilyloxy-4-phenyl-1-butyne; (S)-3-t-butyldimethylsilyloxy-5-phenyl-1-pentyne; (S)-3-t-butyldimethylsilyloxy-4-m-trifluoromethylphenyl-1-butyne; (S)-3-t-butyldimethylsilyloxy-4-endo-bicyclo[3.1.0]-hex-6-yl-1-butyne; (S)-3-t-butyldimethylsilyloxy-4-exo-bicyclo[3.1.0]-hex-6-yl-1-butyne; (S)-3-t-butyldimethylsilyloxy-3-cyclopentyl-1-propyne; (S)-3-t-butyldimethylsilyloxy-3-cyclooctyl-1-propyne; (S)-3-t-butyldimethylsilyloxy-4-cyclopentyl-1-butyne; and (S)-3-t-butyldimethylsilyloxy-4-cyclohexyl-1-butyne. D. Similarly, but starting instead with racemic compounds of formula XVII, prepared according to Preparation 5, the following racemic compounds of formula XX are prepared: 3-t-butyldimethylsilyloxy-1-octyne; 3-t-butyldimethylsilyloxy-1-decyne; 3-t-butyldimethylsilyloxy-1-tridecyne; 3-t-butyldimethylsilyloxy-1-nonyne; 3-t-butyldimethylsilyloxy-4-phenyl-1-butyne; 3-t-butyldimethylsilyloxy-5-phenyl-1-pentyne; 3-t-butyldimethylsilyloxy-4-m-trifluoromethylphenyl-1-butyne; 3-t-butyldimethylsilyloxy-4-endo-bicyclo[3.1.0]hex-6-yl-1-butyne; 3-t-butyldimethylsilyloxy-4-exo-bicyclo[3.1.0]hex-6-yl-1-butyne; 3-t-butyldimethylsilyloxy-3-cyclopentyl-1-propyne; 3-t-butyldimethylsilyloxy-3-cyclohexyl-1-propyne; 3-t-butyldimethylsilyloxy-3-cyclooctyl-1-propyne; 3-t-butyldimethylsilyloxy-4-cyclopentyl-1-butyne; 3-t-butyldimethylsilyloxy-4-cyclohexyl-1-butyne; 3-t-butyldimethylsilyloxy-3-methyl-3-cyclobutyl-1-propyne; and 3-t-butyldimethylsilyloxy-3-methyl-3-cyclopentyl-1-propyne. Preparation 10 A. Preparation of (3′S,1S,2S,3R,6S)-Spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)] (VIII) and (3′S,1R,2R,3S,6R)-Spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0] octane-7,2″-(1″,3″-dioxolane)] (IX) and Related Compounds of Formula VIII and IX. To a mixture of 6.45 g of (S)-3-t-butyldimethylsilyloxy-3-cyclohexyl-1-propyne prepared according to Preparation 9 in 48 ml tetrahydrofuran at 0°C under an argon atmosphere was added over 20 min 15.96 ml of 1.37 M n-butylithium in hexane. The resulting solution was cooled to -78°C and a solution of 3.6 g of (1S*,2S*,4R,7S*)-spiro]3-oxa-9-endo-methyltricyclo-[5.2.0.0 2,4 ]nonane-8,2′-(1′,3′-dioxolane)] in 18 ml tetrahydrofuran was added. To this stirred mixture at -78°C was added a 2.2 ml boron trifluoride etherate dropwise over a 25 min period. To this mixture was added 25 ml saturated sodium sulfate solution. The resulting mixture was warmed to room temperature and it was extracted thoroughly with ethyl acetate. This solution was dried over sodium sulfate and was concentrated in vacuo to give an oily residue, which was further purified by flash chromatography on silica gel using 2% acetone-dichloromethane. This procedure gave 4.6 g of a mixture of the title compounds as an oil. B. In like manner, but replacing the (1S*,2S*,4R*,7S*)-spiro-[3-oxa-9-endo-methyltricyclo [5.2.0.0 2,4 ] nonane-8,2'-(1',3'-dioxolane)] with the 9-exo-methyl isomer and following the procedure of paragraph 10.A. above, the following mixture was prepared: (3'S,1S,2S,3R,6S)-spiro[2-(3'-t-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo [4.2.0]octane-7,2"-(1",3"-dioxolane)]; and (3'S,1R,2R,3S,6R)-spiro[2-(3'-t-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo [4.2.0]octane-7,2"-(1",3"-dioxolane)]. C. Similarly, but starting with other appropriate compounds of formulas XXI and VI or VII, the following mixtures of compounds VIII and IX, where Y is exo-(lower alkyl) or endo-(lower alkyl) are prepared: (3'S,1S,2S,3R,6S)-spiro[2-(3'-t-butyldimethylsilyloxy-dec-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], and (3'S,1R,2R,3S,6R)-spiro[2-(3'-t-butyldimethylsilyloxy-dec-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)]; (3'S,1S,2S,3R,6S)-spiro[2-(3'-t-butyldimethylsilyloxy-tridec-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], and (3'S,1R,2R,3S,6R)-spiro[2-(3'-t-butyldimethylsilyloxy-tridec-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)]; (3'S,1S,2S,3R,6S)-spiro[2-(3'-t-butyldimethylsilyloxy-7'-methylnon-1'-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro(3′-t-butyldimethylsilyloxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo [4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo [4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo [4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]. Preparation 11 A. Preparation of (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)] and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2″,(1″,3″-dioxolane)] and Related Compounds of Formulas XII and XIII. To a mixture of 4.5 g of the diastereomeric mixture of the above titled compounds obtained as described in Preparation 10, in 200 ml of diethyl ether was added 5.1 g of dicobalt octacarbonyl. The resulting solution was stirred at 23°C for 2 hrs. The mixture was diluted with 200 ml diethyl ether and filtered. The filtrate was concentrated to an oil which was purified by flash chromatography using 12% ethyl acetate - hexane to give two components: A (high R f ) and B (low R f ). Component A (2.85 g) was dissolved in 150 ml acetone - water (9:1), to which was added 10.1 g ceric ammonium nitrate. After 2 min. this mixture was diluted with 200 ml water. The product was isolated by extraction with diethyl ether. After drying and evaporation there was obtained 1.5 g of (3′S,1R,2R,3S,6R)-Spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo [4.2.0]octane-7,2″-(1″,3″-dioxolane)] as an oil. Similarly component B (3.26 mg) was converted to (3′S,1R,2R,3S,6R)-Spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo [4.2.0]octane-7,2″-(1″,3″-dioxolane)] as an oil. B. In like manner, but starting instead with the corresponding diastereomeric mixture of VIII and IX where Y is 8-exo-methyl and following the procedure of paragraph 11.A. above, the following compounds were separated: (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-exo-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-Spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-exo-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]. C. Similarly, other compounds of formulas XII and XIII where Y is exo-(lower alkyl) or endo-(lower alkyl) are prepared using the mixtures of VIII and IX from Preparation 10.C.: (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-dec-1-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-dec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-tridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-tridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)], and (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-bUtylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]. (3′S,1S,2S,3R,6S)-spiro[2-(3′-t-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]. Preparation 12 A. Preparation of (3′S,1S,2S,3R,6S)-Spiro[2-(3′-tertbutyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], (3′R,1R,2R,3S,6R)-Spiro[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)] and Related Individual Enantiomers of Formulas XII and XIIA. A mixture of 2.25 g (3′S*,1S*,2S*,3R*,6S*)-spiro[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)], 20 ml ethyldiisopropylamine, 0.76 g 4-dimethylaminopyridine, and 3.65 g (R)-(-)-α-(1-naphthyl)ethylisocyanate is stirred at 45°C for 8 hours. The ethyldiisopropylamine is removed by vacuum evaporation and the residue is dissolved in 100 ml of ethyl acetate. This solution is washed with two 25 ml - portions of 1 N hydrochloric acid, and 25 ml water. After drying over sodium sulfate the solvent is removed by evaporation to leave a residue, which was further purified by silica gel flash chromatography using ethyl acetate-dichloromethane-hexane (7.5:22.5:70). This gives in order of elution: (3'S,1S,2S,3R,6S)-spiro[2-(3'-tertbutyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-0-[(R)-α-(1-naphthyl)-ethylcarbamoyl]-8-endo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], and (3'R,1R,2R,3S,6R)-spiro[2-(-3'-tertbutyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-0-[(R)-α-(1-napthyl) ethylcarbamoyl]-8-endo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)]. Similarly prepared by starting with (3'S*,1S*,2S*,3R*,6S*)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methyl-bicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)] are: (3'S,1S,2S,3R,6S)-spiro[2-(3'tert-butyldimethyl-silyloxy-3'-cyclohexylprop-1'-ynyl)-3-0-[(R)-α-(1-naphthyl)ethylcarbamoyl]-8-exo-methylbicyclo-[4.2.0]octane-7,2"-(1",3"-dioxolane)], and (3'R,1R,2R,3S,6R)-spiro[2-(3'tert-butyldimethyl-silyloxy-3'-cyclohexylprop-1'-ynyl)-3-0-[(R)-α-(1-naphthyl)ethylcarbamoyl]-8-exo-methylbicyclo [4.2.0]octane-7.2"-(1",3"-dioxolane)]. To stirred mixture of 0.3 g lithium aluminum hydride in 50 ml tetrahydrofuran at 0°C is added a solution of 1.25 g of (3'S,1S,2S,3R,6S)-spiro[2-(3'-tert-butyl-dimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-0-[(R)-α-(1-naphthyl)ethylcarbamoyl]-8-endo-methylbicyclo[4.2.0] octane-7,2"-(1",3"-dioxolane)] in 10 ml tetrahydrofuran. This mixture is heated at reflux for 1 hour. After cooling to 23°C the mixture is worked up by sequential dropwise addition of 0.5 ml water, 0.5 ml 15% sodium hydroxide solution, and 1.5 ml water. The resulting solid is separated by filtration and the filtrate evaporated in vacuo. The residue is dissolved in 100 ml ethyl acetate and this solution washed with two 20 ml portions water and then dried over sodium sulfate. Evaporation gives a residue that is purified by silica gel flash chromatography using ethyl acetate-hexane (15:85) to give (3'S,1S,2S,3R,6S)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]octane-7,2"-(1",3"-dioxolane)]. B. Similarly prepared are: (3'R,1R,2R,3S,6R)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], (3'S,1S,2S,3R,6S)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], (3'R,1R,2R,3S,6R)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], (3'S,1R,2R,3S,6R)-spiro[2-(3'tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], (3'R,1S,2S,3R,6S)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], (3'S,1R,2R,3S,6R)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)], and (3'R,1S,2S,3R,6S)-spiro[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7,2"-(1",3"-dioxolane)]. C. In like manner, the following individual compounds of formulas XII and XIIA, (or by starting with XIII in its racemic form the individual compounds of formula XIII and its enantiomer), are obtained, where Y is exo-(lower alkyl) or endo-(lower alkyl): (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-exo-bicyclohex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-exo-bicyclohex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-exo-bicyclohex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-4′-exo-bicyclohex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″-(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″,(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″,(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″,(1″,3″-dioxolane)]; (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octane-7,2″,(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″,(1″,3″-dioxolane)]; (3′S,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″,(1″,3″-dioxolane)]; (3′R,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″,(1″,3″-dioxolane)]; (3′S,1R,2R,3S,6R)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″,(1″,3″-dioxolane)], and (3′R,1S,2S,3R,6S)-spiro[2-(3′-tert-butyldimethylsilyl-oxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octane-7,2″,(1″,3″-dioxolane)]. Preparation 13 A. Preparation of (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octan-7-one and Related Compounds of Formulas XIV and XV. A solution of 110 mg of the (3′S,1S,2S,3R,6S)-cyclohexylpropynyl ketal product of Preparation 11.A. or of Preparation 12.A. where Y is endo-methyl, 3 ml of acetonitrile and 1.5 ml of 2 N sulfuric acid was stirred at ambient temperature for 16 hours. The reaction was quenched by neutralization with aqueous sodium bicarbonate and the mixture was extracted with diethyl ether. The extracts were dried with magnesium sulfate, evaporated to dryness and the residue was purified by short column silica-gel chromatography. Elution with ethyl acetate-hexane (7:3), gave 58 mg (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octan-7-one. B. In like manner, starting with the (3′S,1S,2S,3R,6S)-cyclohexylpropynyl ketal product of Preparation 11.A. or 12.A. where Y is exo-methyl, the following compound of formula XIV was prepared: (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]-octan-7-one. C. In like manner, but starting with other appropriate compounds of Formula XII, the following compounds of formula XIV where Y is exo-(lower alkyl) or endo-lower alkyl are obtained: (3′S,1S,2S,3R,6S)-2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,5′R,1S,2S,3R,6S)-2-(3′-hydroxy-5′-methyl-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,5′R*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-5′-methyl-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-5′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-methyl-4′-phenylbut-1′-ynyl-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-4′-phenylbut-1′-ynyl)3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-3′-methyl-4-phenylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octan-7 -one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]-octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-4′-endo-bicyclo-[3.1.0]hex-6-ylbut-1′ynyl)-3-hydroxy-8-ethylbicyclo-[4.2.0]-octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-4′-exo-bicyclo[3.1.0]-hex-6-ylbut-1′ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo-[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-methyl-3′-cyclopentylprop-1′-ynyl-3-hydroxy-8-ethylbicyclo-[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-4′-endobicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-4′-exo-bicyclo-[3.1.0]hex-6-ylbut-1′-ynyl-3-hydroxy-8-n-propylbicyclo-[4.2.0]-octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]-octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-hydroxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]-octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]-octan-7-one; and (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]-octan-7-one. D. In a similar manner, but starting with other appropriate compounds of formula XIII, the following compounds of formula XV where Y is exo-(lower alkyl) or endo-(lower alkyl) are obtained: (3′S,1R,2R,3S,6R)-2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,5′R,1R,2R,3S,6R)-4-[2-(3′-hydroxy-5′-methyl-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxytridec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,5′R*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-5′-methyl-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxynon-1′-ynyl)-3-hydroxybicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-5′-phenyl]pent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]-octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-4′-endo-bicyclo-[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo-[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-4′-exobicyclo-[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo-[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]-octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-methyl-3′cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo-[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-4′cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-4′-endobicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]-octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-4′-exo-bicyclo-[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo-[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-3′-methyl-3′-cyclobutyprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-hydroxy-3′-methyl-3′-cyclopentyl]prop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-cyclopentyl-prop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]octan-7-one. Preparation 14 A. Preparation of (3'S,1S,2S,3R,6S)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-exo-methylbicyclo-[4.2.0]octan-7-one and related compounds of Formula (XXXIII) and (XXXIV). A mixture of 0.52 g (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)]-3-hydroxy-8-exo-methylbicyclo[4.2.0]octan-7-one, 0.55 g tert-butyldimethylsilyl chloride, 0.18 g 4-dimethylaminopyridine, 2 g of imidazole and 10 ml dichloromethane is stirred at 23°C for 24 hours. After dilution with 20 ml of dichloromethane the mixture is washed with 10 ml water, three 20-ml portions of 1 N HCl and 10 ml sat. sodium bicarbonate. After drying over sodium sulfate the solvent is removed to give the title compound. B. Similarly, starting with the corresponding 8-endo-methyl compound in place of the 8-exo-methyl compound and following the procedure of paragraph 3A above, (3'S,1S,2S,3R,6S)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-endomethylbicyclo[4.2.0]octan-7-one is obtained. C. Similarly, other appropriate compounds of formula (XIV) or (XV), obtained as described in Preparation 13, are converted to the corresponding compounds of formula (XXXIII) or (XXXIV). For example: (3'S,1S,2S,3R,6S)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclooctylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]-octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]-octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentyl-prop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentyl-but-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclohexyl-but-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-ethylbicyclo[4.2.0]octan-7-one; and (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclooctylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-ethylbicyclo[4.2.0]octan-7-one; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-n-propylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethyl silyloxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl--3-tert-butyldimethylsilyloxy-8-n-propylbicyclo-[4.2.0] octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-n-propylbicyclo-[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-n-propylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentyl-prop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-n-propylbicyclo[4.2.0]octan-7-one; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentyl-but-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-n-butylbicyclo[4.2.0]octan-7-one; (3'S*,1R*,2R*,3S*,6R*)-2-(3'-tert-butyldimethylsilyloxy-4'-cyclohexyl-but-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]-octan-7-one; (3'S,1R,2R,3S,6R)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-n-butylbicyclo[4.2.0]-octan-7-one; and (3'S,1R,2R,3S,6R)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-n-butylbicyclo[4.2.0]-octan-7-one. Preparation 15 A. Preparation of (3'S,1S,2S,3R,6S)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)- 3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl- 8-exo-methylbicyclo[4.2.0]octane and related compounds of formula (XXXV) and (XXXVI). A solution of 350 mg of (3'S,1S,2S,3R,6S)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyoxy-8-exo-methylbicyclo-[4.2.0]octan-7-one,prepared as described in Preparation 14, in 1.5 ml of dry tetrahydrofuran under nitrogen is cooled to -78°C and 650 µl of lM vinyl magnesium bromide in tetrahydrofuran is added dropwise. The mixture is stirred for 1 hour at -78°C and the reaction quenched by addition of saturated aqueous ammonium chloride solution. The mixture is extracted with ethyl acetate, the extract dried over sodium sulfate, and solvent removed under reduced pressure. The resulting residue is chromatographed on silica gel to give (3'S,1S,2S,3R,6S)-2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-exo-methylbicyclo[4.2.0]octane. B. In like manner, starting with the corresponding 8-endo-methyl isomer of formula (XXXIII), (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-endo-methylbicyclo[4.2.0]octane was prepared. C. Similarly, starting with the appropriate compounds of formula (XXXIII) or (XXXIV), prepared as described in Preparation 14, any compound of formula (XXXV) or (XXXVI) where Y is exo-(lower alkyl) or endo-(lower alkyl) is prepared, for example: (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclooctylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo[4.2.0]octane; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentylprop-1′ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo[4.2.0]octane; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo[4.2.0]octane; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo[4.2.0]octane; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo[4.2.0]octane; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-exo-bicyclo-[3.1.0]hex-6-ylbut-1′-ynyl-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo[4.2.0]octane; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′cyclobutylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo-[4.2.0]octane; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo-[4.2.0]octane; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentyl-prop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo-[4.2.0]octane; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentyl-but-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo-[4.2.0]octane; (3′S*,1S*,2S*,3R*,6S*)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclohexyl-but-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo-[4.2.0]octane; (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-ethylbicyclo[4.2.0]octane; and (3′S,1S,2S,3R,6S)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-n-butylbicyclo[4.2.0]octane. (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclooctylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-ethylbicyclo[4.2.0]octane; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-ethylbicyclo[4.2.0]octane; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-ethylbicyclo[4.2.0]octane; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclohexylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-ethylbicyclo[4.2.0]octane; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-ethylbicyclo[4.2.0]octane; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-n-propylbicyclo[4.2.0]octane; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-n-propylbicyclo-[4.2.0]octane; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-propylbicyclo-[4.2.0]octane; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentyl-prop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo-[4.2.0]octane; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclopentyl-but-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-methylbicyclo-[4.2.0]octane; (3′S*,1R*,2R*,3S*,6R*)-2-(3′-tert-butyldimethylsilyloxy-4′-cyclohexyl-but-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-n-butylbicyclo-[4.2.0]octane; (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-n-butylbicyclo[4.2.0]octane; and (3′S,1R,2R,3S,6R)-2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-n-butylbicyclo[4.2.0]octane. EXAMPLE 1 Preparation of (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butanoic acid and (E)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butanoic acid and Related Compounds of Formulas (1), (2) and (3) in which R₁ is CO₂H. A. A stock solution of dimsyl sodium was prepared by dissolving 0.6 g sodium hydride in 10 ml dimethyl sulfoxide at 65°C under nitrogen. To a stirred slurry of 1.13 g of 3-carboxypropyltriphenylphosphonium bromide in 5 ml dimethyl sulfoxide under nitrogen was added 4.0 ml of the stock solution of dimsyl sodium. After 20 min at 23°C a solution of 180 mg of (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octan-7-one in 1 ml of dimethyl sulfoxide was added in one portion. After 4 h at 23°C the mixture was poured onto 15 ml 5% sodium carbonate solution. This mixture was washed with two 30 ml portions of ethyl acetate and was then acidified with conc. HCl. The aqueous layer was extracted three times with 50 ml portions of diethyl ether. The combined ether extract was concentrated to 20 ml and this was kept at -20°C for 2 h. The resulting precipitate was filtered and was discarded. Evaporation of the filtrate gave 300 mg of an oil. This material was purified by silica gel flash chromatography using a solvent mixture of acetic acid-ethyl acetate-hexane (0.25:75:25) to give 230 mg of an oil. Further purification by silica gel flash chromatography using a solvent mixture of acetic acid-methanol-dichloromethane (0.2:5.3:94.5) separated the product mixture into the individual compounds of Formulas 2 and 1, respectively. The first eluted was: (E)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butanoic acid, m.p. 43-50°C. The second eluted was: (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butanoic acid, m.p. 46-51°C. B. In like manner, but replacing the (3′S,1S,2S,3R,6S)-2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7-one with other appropriate compounds of formula XIV or XV, obtained as described in Preparation 13, and using 3-carboxypropyltriphenylphosphonium bromide or 4-carboxybutyltriphenylphosphonium bromide, the following compounds of formula (1), (2) and (3) were obtained (E)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butanoic acid, [α] D = -93.8° (C=0.3698, CHCl₃) . (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butanoic acid, m.p. 50-56°C. (E)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]pentanoic acid, m.p. 36-41°C. (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]pentanoic acid, 31-38°C. (E)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]pentanoic acid, [α] D = -71.9° (C=0.4183, CHCl₃) (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicylo-[4.2.0]oct-7-ylidene]pentanoic acid, [α] D = -90.8° (C=0.1928, CHCl₃). C. In like manner, but replacing the (3'S,1S,2S,3R,6S)-2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]octane-7-one with other appropriate compounds of formula XIV, obtained as described in Preparation 13, and using 3-carboxypropyltriphenylphosphonium bromide or 4-carboxybutyltriphenylphosphonium bromide, the following compounds are obtained as individual (Z) and (E) isomers (the compounds of formula (1) and (2) respectively) where Y is endo-(lower alkyl) . (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxyoct-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxyoct-1'-ynyl)-3-hydroxy-8-endo-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxydec-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S,1S,2S,3R,6S)-5-[2-(3'-hydroxytridec-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3'S,5'R,1S,2S,3R,6S)-4-[2-(3'-hydroxy-5'-methylnon-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxynon-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S,1S,2S,3R,6S)-5-[2-(3'-hydroxyoct-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S*,1S*,2S*,3R*,6R*)-4-[2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-5-[2-(3′-hydroxytridec-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S*,5′R*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]-butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxynon-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-5-[2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid. (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]-butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-5-[2-(3′-hydroxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S,1S,2S,3R,6S)-5-[2-(3′-hydroxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-4′-phenyl-but-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-5-[2-(3′-hydroxy-3′-methyl-4-phenylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S*,1S*,2S*,3R*,6S*)-5-[2-(3′-hydroxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-5-[2-(3′-hydroxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-5-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-4'-cyclohexylbut-1'-ynyl)-3-hydroxy-8-endo-ethylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-4'-cyclohexylbut-1'-ynyl)-3-hydroxy-8-endo-n-propylbicyclo-[4.2.0]oct-7-ylidene]butyric acid. (3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-4'-cyclohexylbut-1'-ynyl)-3-hydroxy-8-endo-n-propylbicyclo-[4.2.0]oct-7-ylidene]pentanoic acid; (3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-4'-endo-bicyclo[3.1.0]hex-6-ylbut-1'-ynyl)-3-hydroxy-8-endo-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S*,1S*,2S*,3R*,6S*)-5-[2-(3'-hydroxy-4'-endo-bicyclo[3.1.0]hex-6-ylbut-1'-ynyl)-3-hydroxy-8-endo-n-propylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-4'-exo-bicyclo[3.1.0]hex-6-ylbut-1'-ynyl)-3-hydroxy-8-endo-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-methyl-3'-cyclobutylprop-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-methyl-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3'S*,1S*,2S*,3R*,6S*)-5-[2-(3'-hydroxy-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-4'-cyclopentylbut-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo-[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-endo-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; D. In like manner using the appropriate compounds of formula XV, obtained as described in Preparation 13, the following compounds of formula (3) are obtained, where Y is endo-(lower alkyl). (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-5-[2-(3′-hydroxytridec-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (Z)-(3′S,5′R,1R,2R,3S,6R)-4-[2-(3′-hydroxy-5′-methylnon-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxynon-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-5-[2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-5-[2-(3′-hydroxytridec-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (Z)-(3′S*,5′R*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-5′-methyl-non-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxynon-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-5-[2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-4′-phenylpent-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-5-[2-(3′-hydroxy-3′-methyl-4′-phenylbut-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (Z)-(3′S,1R,2R,3S,6R)-5-[2-(3′-hydroxy-4′-m-trifluoromethylphenylbut-1′-ynyl)-3-hydroxy-8-endo-ethylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-endo-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-endo-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-endo-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S*,1R*,2R*,3S*,6R*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-n-propylbicyclo-[4.2.0]-oct-7-ylidene]butyric acid; (Z)-(3'S*,1R*,2R*,3S*,6R*)-5-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo-[4.2.0]-oct-7-ylidene]pentanoic acid; (Z)-(3'S*,1R*,2R*,3S*,6R*)-4-[2-(3'-hydroxy-4'-cyclohexylbut-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo-[4.2.0]-oct-7-ylidene]butyric acid; (Z)-(3'S*,1R*,2R*,3S*,6R*)-5-[2-(3'-hydroxy-4'-cyclohexylbut-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo-[4.2.0]oct-7-ylidene]pentanoic acid; (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexyl-prop-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexyl-but-1'-ynyl)-3-hydroxy-8-endo-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; EXAMPLE 2 A. Alternative preparation of (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]-butanoic acid and (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methyl-bicyclo[4.2.0]oct-7-ylidene]butanoic acid and Related Compounds of Formulas (1), (2) and (3) in which R₁ is CO₂H. (a) A solution of 100 mg of (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-7-hydroxy-7-vinyl-8-endo-methylbicyclo[4.2.0]octane, prepared as shown in Preparation 15, 5µl of acetic acid and 0.6 ml of triethyl orthoacetate is heated at 120°C for 20 hrs. The excess reactants are then removed under reduced pressure and the residue chromatographed on silica gel, eluting with 10% ethyl acetate in hexane to give a mixture of the (E) and (Z) isomers of ethyl (3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyrate. (b) The mixture of the (E) and (Z) isomers is dissolved in 1 ml of a mixture of 1N sulfuric acid-acetonitrile (1:1) and stirred at room temperature for 48 hours. The reaction mixture is then poured into water, extracted with ethyl acetate, the extract dried over sodium sulfate and solvent removed under reduced pressure. The residue is treated with 2 ml of 0.5 M lithium hydroxide in methanol, stirring for 16 hours at room temperature. The reaction mixture is then acidified with 0.5 M potassium bisulfate and extracted with ethyl acetate. The organic layer is washed with brine, dried over sodium sulfate and the solvent removed under reduced pressure. The residue is chromatographed on silica gel eluting with a mixture of acetic acid-methanol-dichloromethane (0.2: 5.3 :94.5), to give (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]-butanoic acid and (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methyl-bicyclo[4.2.0]oct-7-ylidene]butanoic acid. B. In like manner, starting with the corresponding 8-exo-methyl isomer of formula (XXXV), (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo-[4.2.0]oct-7-ylidene]-butanoic acid and (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methyl-bicyclo[4.2.0]oct-7-ylidene]butanoic acid are obtained. C. In like manner, starting with the appropriate compounds of formula (XXXV) or (XXXVI), obtained as described in Preparation 15, the following compounds of formula (1), (2) and (3) where Y is exo-(lower alkyl) or endo-(lower alkyl) are obtained as individual (E) and (Z) isomers: (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,5′R,1S,2S,3R,6S)-4-[2-(3′-hydroxy-5′-methyl-non-1′-ynyl)-3-hydroxy-8-n-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxynon-1′-ynyl)-3-hydroxybicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxyoct-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxydec-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,5′R*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-5′-methyl-non-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]-butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxynon-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-phenylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-4′-phenyl-but-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′ -ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclopentylprop-1-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclooctylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-5′-phenylpent-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-4′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-4′-cyclopentylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-4′-cyclohexylbut-1′-ynyl)-3-hydroxy-8-n-propylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-4′-endo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-4′-exo-bicyclo[3.1.0]hex-6-ylbut-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclobutylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-3′-methyl-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-4′-cyclopentylbut-1-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid; and (Z)-(3′S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyric acid. EXAMPLE 3 Preparation of methyl Z-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene]butyrate, related compounds of Formula XXVIII, and other pharmaceutically acceptable esters. A. To a solution of 0.5g Z-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid in 10 ml diethyl ether is added excess ethereal diazomethane until the yellow color persisted. Evaporation of solvent gives the title compound. B. In a similar manner, starting from Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid and following the procedure of paragraph 3A above, methyl Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate is obtained. C. In like manner, but starting with other appropriate compounds of formulas (1), (2), and (3) where Y is exo-(lower alkyl) or endo-(lower alkyl), the following exemplary esters are obtained: methyl (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate; methyl (Z)-(3S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cycloprop-1'-ynyl)-3-hydroxybicyclo[4.2.0]oct-7-ylidene]butyrate; methyl (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate; methyl (E)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate; methyl (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate; methyl (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate; methyl (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-ethylbicyclo-[4.2.0]oct-7-ylidene]butyrate; and methyl (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]oct-7-ylidene]butyrate. EXAMPLE 4 Compounds Wherein R₁ is CH₂OH A. Preparation of methyl Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-exo-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate and related compounds of Formula XXIX. A mixture of 0.52 g methyl Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene]butyrate, 0.55 g tert-butyldimethylsilyl chloride, 0.18 g 4-dimethylaminopyridine, 2 ml triethylamine and 10 ml dichloromethane is stirred at 23°C for 24 hours. After dilution with 20 ml of dichloromethane the mixture is washed with 10 ml water, three 20-ml portions of 1 N HCl and 10 ml sat. sodium bicarbonate. After drying over sodium sulfate the solvent is removed to give the title compound. B. Similarly, starting with the corresponding 8-endo-methyl compound in place of the 8-exo-methyl and following the procedure of paragraph 4A above, methyl Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyrate is prepared. C. Similarly, but starting with other appropriate esters of Formula XXVIII, the following compounds of Formula XXIX where Y is exo-(lower alkyl) or endo-(lower alkyl) are prepared: Methyl (Z)-(3′S,1S,2S,3R,6S)-5-[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tertbutyldimethylsilyloxy-8-methylbicyclo[4.2.0]-oct-7-ylidene]pentanoate; methyl (Z)-(3S*,1S*,2S*,3R*,6S*)-4-[2-(3′-tert-butyldimethylsilyloxy-3′-cycloprop-1′-ynyl)-3-tertbutyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; methyl (E)-(3′S,1S,2S,3R,6S)-4-[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; methyl (E)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyl-dimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; methyl (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; Methyl (Z)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-tert-butyldimethylsilyloxy-3′-cyclopentylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; methyl (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]butyrate; and methyl (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-tert-butyldimethylsilyloxy-3′-cyclohexylprop-1′-ynyl)-3-tert-butyldimethylsilyloxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]butyrate. D. Preparation of Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-exo-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol and related compounds of Formula XXX. To a stirred mixture of 2.5 ml of 1M lithium aluminum hydride in 5 ml diethyl ether is added in dropwise fashion a solution of 0.78 g of methyl Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-exo-methylbicyclo[4.2.0]-oct-7-ylidene]butyrate in 5 ml of diethyl ether. This mixture is stirred at 0°C for 30 minutes. The reaction is worked up by sequential dropwise addition of 2 ml of saturated sodium sulfate solution and 0.3 ml water. The resulting precipitate is removed by filtration. Evaporation of the filtrate gives 0.4 g of the title compound. E. Similarly, starting with the corresponding 8-endo-methyl compound in place of the 8-exo-methyl and following the procedure of 40 above, Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol is prepared. F. In a similar manner, but starting instead with other appropriate compounds of Formula XXIX, prepared according to the method described in paragraph A above, the following compounds of Formula XXX where Y is exo-(lower alkyl) or endo-(lower alkyl) are prepared: (Z)-(3'S,1S,2S,3R,6S)-5-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]-oct-7-ylidene]-1-pentanol; (Z)-(3S*,1S*,2S*,3R*,6S*)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cycloprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanol; (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylildene]-1-butanol; (E)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanol; (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclopentylprop-1-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanol; (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclopentylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanol; (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1-ynyl)-3-tert-butyldimethylsilyloxy-8-ethylbicyclo[4.2.0]oct-7-ylidene]-1-butanol; and (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1-ynyl)-3-tert-butyldimethylsilyloxy-8-n-butylbicyclo[4.2.0]oct-7-ylidene]-1-butanol. G. Preparation of Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanol and related compounds of Formulas (1), (2) and (3) where Y is exo-methyl or endo-methyl in which R₁ is CH₂OH. To a solution of 0.15 g Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-exo-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol in 3 ml tetrahydrofuran was added 5 ml of a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran. After 12 hours at 23°C the solution is diluted with 20 ml water and the product is extracted into diethyl ether. Evaporation of the solvent and purification of the product using silica gel flash chromatography with ethyl acetate-hexane (1:1) gave 0.8 g of the title compound. H. Similarly, starting with the corresponding 8-endo-methyl compound in place of the 8-exo-methyl and following the procedure of paragraph 3G above, Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanol is prepared. I. In like manner, but starting with other compounds of Formula XXX, preparation of which is described in paragraph D of this Example, the following compounds of formulas (1), (2), and (3) in which R₁ is CH₂OH and Y is exo-(lower alkyl) or endo-(lower alkyl) are prepared: (Z)-(3'S,1S,2S,3R,6S)-5-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-pentanol; (Z)-(3S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cycloprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol; (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol; (E)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol; (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol; and (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanol. EXAMPLE 5 Preparation of Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanal and related compounds of Formulas (1), (2) and (3) wherein R₁ is CHO. A. To a stirred mixture of 0.25 g pyridinium chlorochromate in 7 ml dichloromethane is added a solution of 0.2 g Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-tert-butyldimethylsilyloxy-3'-cyclohexylprop-1'-ynyl)-3-tert-butyldimethylsilyloxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanol, prepared according to Example 3.A., in 3 ml dichloromethane. After 4 hours at 23°C the solution is decanted from the precipate and is filtered through 10 g Florisil® with dichloromethane. The filtrate is concentrated to a residue, which is dissolved in 3 ml tetrahydrofuran. To this solution is added 2 ml of a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran. After 16 hours at 23°C this solution is diluted with 20 ml water and the product is extracted into diethyl ether. Evaporation of solvent followed by silica gel flash chromatography using ethyl acetate-hexane (30:70) gives the title compound. B. Similarly, starting with the corresponding 8-endo-methyl compound in place of the 8-exo-methyl and following the procedure of 5A above, (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-2'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]-1-butanal is prepared. C. In a similar manner, but starting with other appropriate compounds of Formula XXX where Y is exo-(lower alkyl) or endo-(lower alkyl), preparation of which is described in Example 4, the following compounds of Formulas (1), (2), and (3) in which R₁ is CHO and Y is exo-methyl or endo-methyl are prepared: (Z)-(3'S,1S,2S,3R,6S)-5-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-pentanal; (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cycloprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanal; (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanal; (E)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanal; (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclopentylprop-1-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanal; (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclopentylprop-1'-ynyl)-3-hydroxy-8-methylbicyclo-[4.2.0]oct-7-ylidene]-1-butanal; (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1-ynyl)-3-hydroxy-8-ethylbicyclo-[4.2.0]oct-7-ylidene]-1-butanal; and (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-n-butylbicyclo-[4.2.0]oct-7-ylidene]-1-butanal. EXAMPLE 6 Preparation of p-Benzamidophenyl Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methylbicyclo[4.2.0]oct-7-ylidene]butyrate, and related compounds of Formulas (1), (2), and (3) in which R₁ is CO₂R and Y is exo-methyl or endo-methyl. A. A solution of Z-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-exo-methyl-bicyclo[4.2.0]oct-7-ylidene]butyric acid (35 mg, 0.101 mmol) in acetone (2.7 mℓ) is treated with triethylamine (28.1 µℓ, 0.202 mmol). The solution is cooled to -5°C under N₂ and isobutyl chlorocarbonate (27.3 µℓ, 0.202 mmol) is added. After 5 min at -5°C, a solution of p-benzamidophenol (109.2 mg, 0.51 mmol) in dry pyridine (1.1 mℓ) is added. After 3 h at room temperature, the solvent is removed under vacuum. The residue is extracted with dichloromethane and the solid (excess p-benzamidophenol) is removed by filtration. After evaporation of the solvent, the residue is purified by column chromotography using 30% acetone in hexane to afford the title compound. B. In a similar manner, starting from the corresponding 8-endo-methyl compound in place of the 8-exo-methyl and following the procedures of paragraph 6A above, p-benzamidophenyl Z-(3'S,1S,2S,3S,6S)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo-[4.2.0]oct-7-ylidene]butyrate is prepared. C. In like manner, but starting with other appropriate compounds of Formulas (1), (2), or (3), in which R₁ is CO₂H, Y is exo-methyl or endo-methyl and substituting for the p-benzamidophenol other appropriate substituted phenols, the corresponding exemplary compounds in which R₁ is CO₂R are prepared: p-acetylphenyl (Z)-(3′S,1S,2S,3R,6S)-5-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]pentanoate; p-benzoylphenyl (Z)-(3S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cycloprop-1′-ynyl)-3-hydroxybicyclo[4.2.0]oct-7-ylidene]butyrate; p-N′,N′-dimethylureidophenyl (E)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; p-benzamidophenyl (E)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; p-benzoylphenyl (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]oct-7-ylidene]butyrate; and p-methylureidophenyl (Z)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclopentylprop-1′-ynyl)-3-hydroxy-8-methylbicyclo[4.2.0]-oct-7-ylidene]butyrate. EXAMPLE 7 Inhibition of Platelet Aggregation Human venous blood from drug-free healthy volunteers was collected into 15 ml-vacutainers and anticoagulated with 0.5 ml of 11.4 % sodium citrate. The blood was centrifuged at room temperature for 15 minutes at 150 g in a Sorvall GLC-28 centrifuge and the supernant platelet-rich plasma (PRP) was collected by aspiration. Platelet-poor plasma (PPP) was prepared by centrifuging the blood from which PRP had been removed at 12,800 g for 3 minutes in an Eppendorf centrifuge at room temperature. Platelet aggregation was carried out by the method of Born (J. Physiology, 168 , 178 (1963)) in Payton aggregometers. Platelet aggregation was induced by adding ADP (2-5 nmoles) into 1 ml of PRP containing 10 µl of various concentrations of test compounds or vehicle incubated in the aggregometer cuvette at 37°C for 5 minutes with the stirring speed set at 500 rpm. Then, for each test compound, a percent inhibition versus concentration curve was drawn on semi-logarithmic paper and the concentration corresponding to 50% inhibition was expressed as the IC₅₀ of this compound. All the test compounds (1-2 mg) were prepared as 0.01 M stock solutions in 10% ethanol and 59 mM Na₂CO₃. Subsequent dilutions were made with water. The following table summarizes the test results: EXAMPLE 8 Antihypertensive Activity The antihypertensive effects of the prostaglandin-like compounds were evaluated in spontaneously hypertensive rats (SHR/NCrlBR). Under ether anesthesia, femoral arterial and venous cannulae were implanted and the rats were restrained in a supine position. After recovery from the anesthesia, lidocaine was administered. Blood pressures were obtained via the femoral arterial cannula and recorded on a Beckman R611 polygraph. Groups of four rats were studied for each compound. Vehicle was administered at the beginning of the study and compound was intravenously administered at 30 min intervals thereafter, at increasing doses of 1, 3, 10, 30 and 100 µg/Kg. Baseline mean arterial blood pressure was the blood pressure immediately prior to the first dose of the compound. ED₂₀s were calculated from a linear regression of the percent decrease of mean blood pressures following each dose of the compound. EXAMPLE 9 Toxicity Guinea pigs weighing about 350-550 g were given 1mg/Kg of the test compound (Z)-(3'S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene)butyric acid in solution once orally. No toxic effects were observed. Other compounds of the invention also exhibit no toxic effects.

Claims: A compound of formula (1), (2) or (3) wherein: Y is exo-(lower alkyl) or endo-(lower alkyl); n is 2 or 3; R₁ is CH₂OH, CHO, CO₂R or CO₂H; R₂ is hydrogen or methyl; and R₃ is linear or branched alkyl having 5-10 carbon atoms, optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen. in which a is 0, 1 or 2; b is 3-7; m is 1 or 2; and R is wherein X is in which each R₄ is independently hydrogen or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof. A compound of claim 1 wherein Y is exo-methyl, endo-methyl, exo-ethyl or endo-ethyl, R₁ is CO₂H, CO₂R of CHO; and R₃ is linear or branched alkyl of 5 to 10 carbons, or and the pharmaceutically acceptable, non-toxic salts and esters thereof. A compound of claim 2 wherein R³ is linear or branched alkyl of 5 to 7 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof. A compound of claim 3 wherein R₁ is CO₂R or CO₂H, and R₃ is n-pentyl, and the pharmaceutically acceptable, non-toxic salts and esters thereof. A compound of claim 3 wherein R₁ is CO₂R or CO₂H, and R₃ is and the pharmaceutically acceptable non-toxic salts and esters thereof. A compound of claim 5 wherein n is 2, R₁ is CO₂H, R₂ is hydrogen, and R₃ is and the pharmaceutically acceptable, non-toxic salts and esters thereof. A compound of claim 6 wherein a is 0 or 1 and the pharmaceutically acceptable non-toxic salts and esters thereof. A compound of claim 7 wherein a is 0 and b is 5, and the pharmaceutically acceptable, non-toxic, salts and esters thereof. A compound of Claim 5 wherein n is 3 and a is 0 or 1, and the pharmaceutically acceptable non-toxic salts and ester thereof. A compound of Claim 8 in which Y is endo-methyl, namely (Z)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid, (Z)-(3,S,1R,2R,3S,6R)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid, or (E)-(3′S,1S,2S,3R,6S)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid and the pharmaceutically acceptable non-toxic salts and esters thereof. The racemic modification of the compound of Claim 10, namely (Z)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid, (Z)-(3′S*,1R*,2R*,3S*,6R*)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid, or (E)-(3′S*,1S*,2S*,3R*,6S*)-4-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid and the pharmaceutically acceptable non-toxic salts and esters thereof. A compound of Claim 9 in which a is 0, b is 5 and Y is endo-methyl, namely (Z)-(3′S,1S,2S,3R,6S)-5-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid, (Z)-(3′S,1R,2R,3S,6R)-5-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-y-ylidene]pentanoic acid, or (E)-(3′S,1S,2S,3R,6S)-5-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]pentanoic acid and the pharmaceutically acceptable non-toxic salts and esters thereof. The racemic modification of the compound of Claim 12, namely (Z)-(3′S*,1S*,2S*,3R*,6S*)-5-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methyl-bicyclo[4.2.0]oct-7-ylidene]pentanoic acid, (Z)-(3′S*,1R*,2R*,3S*,6R*)-5-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methyl-bicyclo-[4.2.0]oct-7-ylidene]pentanoic acid, or (E)-(3′S*,1S*,2S*,3R*,6S*)-5-[2-(3′-hydroxy-3′-cyclohexylprop-1′-ynyl)-3-hydroxy-8-endo-methyl-bicyclo[4.2.0]oct-7-ylidene]pentanoic acid and the pharmaceutically acceptable non-toxic salts and esters thereof. The use of a compound of any one of claims 1 to 13 in the manufacture of a medicament for treating cardiovascular disorders. The use of Claim 14 wherein the disorder is atherosclerosis. The use of Claim 14 wherein the disorder involves a thrombotic condition. The use of Claim 14 wherein the disorder involves a vasospastic condition. The use of Claim 14 wherein the disorder is hypertension. The use of Claim 14 wherein the disorder is elevated cholesterol levels. The use of a compound of any one of claims 1 to 13 in the manufacture of a medicament for inhibiting gastric acid secretion. A pharmaceutical composition containing at least one suitable pharmaceutical excipient and a compound of any one of claims 1 to 13 or a pharmaceutically acceptable, non-toxic salt or ester thereof. A process for preparing a compound of formula (1), (2) or (3) wherein: Y is exo-(lower alkyl) or endo-(lower alkyl); n is 2 or 3; R₁ is CH₂OH, CHO, CO₂R or CO₂H; R₂ is hydrogen or methyl; and R₃ is linear or branched alkyl having 5-10 carbon atoms, optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen. in which a is 0, 1 or 2; b is 3-7; m is 0, 1 or 2; and R is wherein X is in which each R₄ is independently hydrogen or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof, which process comprises: (a) reacting a compound of the formula with an appropriately chosen stabilized anion or ylid of formula wherein P′ is a residue normally associated with olefination reactions, n is 2 or 3 and R₁ is as defined above or protected derivative or salt thereof, to obtain a mixture of compounds of formula (1) and formula (2) or a mixture of compound (3) and its corresponding E-compound, followed by separation of the mixtures; or (b) removing protecting groups in a compound of the formula to obtain a compound of formula (1), (2) or (3); or (c) removing protecting group in a compound of the formula to obtain a compound of formula (1), (2) or (3) wherein R₁ is CH₂OH; and the following optional steps: (d) converting a compound of formula (1), (2), or (3) wherein R₁ is CO₂H to the corresponding compound wherein R₁ is CH₂OH; or (e) converting a compound for formula (1), (2) or (3) wherein R₁ is CO₂H to the corresponding compound wherein R₁ is CHO; or (f) converting a compound of formula (1), (2) or (3) wherein R₁ is CO₂H to the corresponding compound wherein R₁ is CO₂R; and the following optional steps: (g) converting an acid of formula (1), (2) or (3) to a pharmaceutically acceptable, non-toxic salt; and (h) converting a pharmaceutically acceptable, non-toxic salt of the compound of formula (1), (2) or (3) to its corresponding acid or ester; and (i) converting an acid of formula (1), (2) or (3) to a pharmaceutically acceptable, non-toxic ester; and (j) converting a pharmaceutically acceptable, non-toxic ester of the compound of formula (1), (2) or (3) to its corresponding acid or salt; and (k) converting a pharmaceutically acceptable, non-toxic ester of the compound of formula (1), (2) or (3) to another pharmaceutically acceptable, non-toxic ester; and (l) converting a pharmaceutically acceptable, non-toxic salt of the compound of formula (1), (2) or (3) to another pharmaceutically acceptable, non-toxic salt. A process according to claim 22 wherein the active ingredient prepared in accordance with claim 22 is mixed with a pharmaceutically acceptable carrier. A compound according to any one of claims 1 to 13 for use as a medicament. Claims for the following Contracting States : AT, ES, GR A process for preparing a compound of formula (1), (2) or (3) wherein: Y is exo-(lower alkyl) or endo-(lower alkyl); n is 2 or 3; R₁ is CH₂OH, CHO, CO₂R or CO₂H; R₂ is hydrogen or methyl; and R₃ is linear or branched alkyl having 5-10 carbon atoms, optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen. in which a is 0, 1 or 2; b is 3-7; m is 1 or 2; and R is wherein X is in which each R₄ is independently hydrogen or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof, which process comprises: (a) reacting a compound of the formula with an appropriately chosen stabilized anion or ylid of formula wherein P' is a residue normally associated with olefination reactions, n is 2 or 3 and R₁ is as defined above or protected derivative or salt thereof, to obtain a mixture of compounds of formula (1) and formula (2) or a mixture of compound (3) and its corresponding ε-compound, followed by separation of the mixtures; or (b) removing protecting groups in a compound of the formula to obtain a compound of formula (1), (2) or (3); or (c) removing protecting group in a compound of the formula to obtain a compound of formula (1), (2) or (3) wherein R₁ is CH₂OH; and the following optional steps: (d) converting a compound of formula (1), (2) or (3) wherein R₁ is CO₂H to the corresponding compound wherein R₁ is CH₂OH; or (e) converting a compound of formula (1), (2) or (3) wherein R₁ is CO₂H to the corresponding compound wherein R₁ is CHO; or (f) converting a compound of formula (1), (2) or (3) wherein R₁ is CO₂H to the corresponding compound wherein R₁ is CO₂R; and the following optional steps: (g) converting an acid of formula (1), (2) or (3) to a pharmaceutically acceptable, non-toxic salt; and (h) converting a pharmaceutically acceptable, non-toxic salt of the compound of formula (1), (2) or (3) to its corresponding acid or ester; and (i) converting an acid of formula (1), (2) or (3) to a pharmaceutically acceptable, non-toxic ester; and (j) converting a pharmaceutically acceptable, non-toxic ester of the compound of formula (1), (2) or (3) to its corresponding acid or salt; and (k) converting a pharmaceutically acceptable, non-toxic ester of the compound of formula (1), (2) or (3) to another pharmaceutically acceptable, non-toxic ester; and (l) converting a pharmaceutically acceptable, non-toxic salt of the compound of formula (1), (2) or (3) to another pharmaceutically acceptable, non-toxic salt. The process of claim 1 wherein a compound in which Y is exo-methyl, endo-methyl, exo-ethyl or endo-ethyl, R₁ is CO₂H, CO₂R or CHO; and R₃ is linear or branched alkyl of 5 to 10 carbons, and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 2 wherein a compound in which R³ is linear or branched alkyl of 5 or 7 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 3 wherein a compound in which R₁ is CO₂R or CO₂H, and R₃ is n-pentyl, and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 3 wherein a compound in which R₁ is CO₂R or CO₂H, and R₃ is and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 5 wherein a compound in which n is 2, R₁ is CO₂H, R₂ is hydrogen and R₃ is and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 6 wherein a compound in which a is 0 or 1 and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 7 wherein a compound in which a is 0 and b is 5, and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 5 wherein a compound in which n is 3 and a is 0 or 1, and the pharmaceutically acceptable, non-toxic salts and esters thereof are prepared. The process of claim 8 wherein a compound in which Y is endo-methyl is prepared, namely (Z)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexyl-prop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene]butyric acid, (Z)-(3'S,1R,2R,3S,6R)-4-[2-(3'-hydroxy-3'-cyclohexyl-prop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene]butyric acid, or (E)-(3'S,1S,2S,3R,6S)-4-[2-(3'-hydroxy-3'-cyclohexyl-prop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene]butyric acid and the pharmaceutically acceptable non-toxic salts and esters thereof. The process of claim 10 wherein a racemic modification of the compound of claim 10 is prepared, namely (Z)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid, (Z)-(3'S*,1R*,2R*,3S*,6R*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]oct-7-ylidene]butyric acid, or (E)-(3'S*,1S*,2S*,3R*,6S*)-4-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4-2.0]oct-7-ylidene]butyric acid and the pharmaceutically acceptable non-toxic salts and esters thereof. The process of claim 9 wherein a compound in which a is 0, b is 5 and Y is endo-methyl is prepared, namely (Z)-(3'S,1S,2S,3R,6S)-5-[2-(3'-hydroxy-3'-cyclohexyl-prop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene]pentanoic acid, (Z)-(3'S,1R,2R,3S,6R)-5-[2-(3'-hydroxy-3'-cyclohexyl-prop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene]pentanoic acid, or (E)-(3'S,1S,2S,3R,6S)-5-[2-(3'-hydroxy-3'-cyclohexyl-prop-1'-ynyl)-3-hydroxy-8-endo-methylbicyclo[4.2.0]-oct-7-ylidene]pentanoic acid and the pharmaceutically acceptable non-toxic salts and esters thereof. The process of Claim 10 wherein a racemic modification of the compound of claim 12 is prepared, namely (Z)-(3'S*,1S*,2S*,3R*,6S*)-5-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methyl-bicyclo-[4.2.0]oct-7-ylidene]pentanoic acid, (Z)-(3'S*,1R*,2R*,3S*,6R*)-5-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methyl-bicyclo-[4.2.0]oct-7-ylidene]pentanoic acid, or (E)-(3'S*,1S*,2S*,3R*,6S*)-5-[2-(3'-hydroxy-3'-cyclohexylprop-1'-ynyl)-3-hydroxy-8-endo-methyl-bicyclo-[4.2.0]oct-7-ylidene]pentanoic acid and the pharmaceutically acceptable non-toxic salts and esters thereof. The use of a compound prepared in accordance with any one of claims 1 to 13 in the manufacture of a medicament for treating cardiovascular disorders. The use of Claim 14 wherein the disorder is atherosclerosis. The use of Claim 14 wherein the disorder involves a thrombotic condition. The use of Claim 14 wherein the disorder involves a vasospastic condition. The use of Claim 14 wherein the disorder is hypertension. The use of Claim 14 wherein the disorder is elevated cholesterol levels. The use of a compound prepared in accordance with any one of claims 1 to 13 in the manufacture of a medicament for inhibiting gastric acid secretion. The process of any one of claims 1 to 13 wherein the active ingredient prepared is mixed with a pharmaceutically acceptable carrier.

Inventors: KLUGE, ARTHUR F., WU, HELEN Y.
Applicants: SYNTEX (U.S.A.) INC.
Application year: 1987
Main classification: C07C59
IPC codes: A61K31, C07C275, C07C67, C07C233, C07C45, A61P1, A61P9, A61P7, C07C49, C07C27, A61P3, C07C59, C07C47, C07C69, C07C35, C07C231